Biochemistry

Amino acids, protein structure, enzyme kinetics, carbohydrate metabolism, lipid metabolism, nucleotide metabolism, vitamins, cofactors, and every metabolic pathway, enzyme deficiency, and clinical correlation across the full scope of medical biochemistry.

01 Overview & Scope of Medical Biochemistry

Biochemistry is the study of chemical processes within and relating to living organisms. In medical education, it serves as the molecular foundation for understanding physiology, pharmacology, pathology, and genetics. Virtually every clinical discipline relies on biochemical principles—from diabetic ketoacidosis in the emergency department to enzyme replacement therapy for lysosomal storage diseases, from pharmacokinetics in anesthesia to tumor metabolism in oncology.

Why This Matters

A solid command of biochemistry is essential for interpreting lab values, understanding drug mechanisms, diagnosing inborn errors of metabolism, and reasoning through the metabolic derangements encountered in critical care, endocrinology, and nearly every other clinical specialty.

Core Domains of Medical Biochemistry

DomainScopeClinical Relevance
Amino acids & proteinsStructure, folding, hemoglobin, collagenSickle cell disease, osteogenesis imperfecta, Ehlers-Danlos
Enzyme kineticsMichaelis-Menten, inhibition, regulationDrug design (competitive vs. non-competitive inhibitors), enzymopathies
Carbohydrate metabolismGlycolysis, TCA, ETC, gluconeogenesis, glycogenDiabetes, glycogen storage diseases, lactic acidosis
Lipid metabolismBeta-oxidation, ketogenesis, lipoproteins, cholesterolFamilial hypercholesterolemia, DKA, fatty acid oxidation defects
Nucleotide metabolismPurine/pyrimidine synthesis & degradationGout, Lesch-Nyhan syndrome, chemotherapy targets
Vitamins & cofactorsFat-soluble (ADEK), water-soluble (B, C)Scurvy, beriberi, pellagra, rickets, coagulopathy
Molecular biologyDNA replication, transcription, translation, repairXeroderma pigmentosum, Lynch syndrome, antibiotics
Biochemistry accounts for roughly 14–18% of USMLE Step 1 questions. The highest-yield topics are metabolic pathways and their rate-limiting enzymes, vitamin deficiencies, and inborn errors of metabolism.

02 Water, pH & Buffer Systems

Water constitutes approximately 60% of body mass and serves as the universal solvent for biochemical reactions. Its unique properties—high heat capacity, high heat of vaporization, and ability to form hydrogen bonds—make it indispensable for life. The Henderson-Hasselbalch equation (pH = pKa + log [A]/[HA]) is the central relationship for understanding buffer chemistry and acid-base physiology.

Physiological Buffer Systems

Buffer SystemLocationpKaClinical Significance
Bicarbonate / CO2Blood (extracellular)6.1Primary extracellular buffer; regulated by lungs (CO2) and kidneys (HCO3)
Phosphate (H2PO4/HPO42−)Intracellular, urine6.8Major intracellular buffer; important renal titratable acid
HemoglobinRed blood cells~7.0Buffering by histidine residues; Bohr effect links pH to O2 release
Proteins (albumin)Blood, intracellularVariableHistidine, glutamate, aspartate side chains accept/donate protons
The Bicarbonate Buffer System

CO2 + H2O ↔ H2CO3 ↔ H+ + HCO3. Carbonic anhydrase catalyzes the first reaction. Despite a pKa of 6.1 (far from blood pH 7.4), this system is the most effective blood buffer because both components are independently regulated: the lungs control CO2 and the kidneys control HCO3, making it an open buffer system.

Amino Acid Titration & pI

Each amino acid has characteristic pKa values for its α-amino group (~9.0), α-carboxyl group (~2.0), and side chain (if ionizable). The isoelectric point (pI) is the pH at which the net charge is zero. For amino acids without ionizable side chains, pI = (pKa1 + pKa2)/2. For acidic AAs (Asp, Glu), pI = average of the two lowest pKa values; for basic AAs (Lys, Arg, His), pI = average of the two highest pKa values.

At physiological pH (7.4), amino acids exist predominantly as zwitterions. Histidine (pKa ~6.0 for the imidazole side chain) is the only amino acid whose side chain is significantly protonated/deprotonated near physiological pH, making it a superb physiological buffer and a frequent player in enzyme active sites.

Acid-Base Disorders at a Glance

DisorderpHPrimary ChangeCompensationCommon Causes
Metabolic acidosis↓ HCO3↓ pCO2 (hyperventilation)DKA, lactic acidosis, renal failure, diarrhea, RTA
Metabolic alkalosis↑ HCO3↑ pCO2 (hypoventilation)Vomiting, diuretics, Cushing, Conn syndrome
Respiratory acidosis↑ pCO2↑ HCO3 (renal retention)COPD, hypoventilation, airway obstruction, opioids
Respiratory alkalosis↓ pCO2↓ HCO3 (renal excretion)Anxiety/hyperventilation, high altitude, PE, early sepsis

Anion Gap

The anion gap (AG) = Na+ − (Cl + HCO3); normal = 8–12 mEq/L. Elevated AG metabolic acidosis indicates accumulation of unmeasured anions. Mnemonic for causes: MUDPILES — Methanol, Uremia, DKA, Propylene glycol, Iron/Isoniazid, Lactic acidosis, Ethylene glycol, Salicylates. Normal AG (hyperchloremic) acidosis: diarrhea, RTA types I & II, acetazolamide, normal saline infusion.

03 Thermodynamics & Bioenergetics

Biochemical reactions obey the laws of thermodynamics. The Gibbs free energy change (ΔG) determines whether a reaction proceeds spontaneously. ΔG < 0 indicates an exergonic (spontaneous) reaction; ΔG > 0 indicates an endergonic (nonspontaneous) reaction. ΔG depends on ΔG°′ (standard free energy change at pH 7) and the actual concentrations of reactants/products: ΔG = ΔG°′ + RT ln Q.

High-Energy Compounds

CompoundΔG°′ of Hydrolysis (kJ/mol)Function
Phosphoenolpyruvate (PEP)−61.9Highest phosphoryl-transfer potential; glycolysis substrate
1,3-Bisphosphoglycerate−49.4Glycolysis intermediate; substrate-level phosphorylation
Creatine phosphate−43.1Rapid ATP regeneration in muscle and brain
ATP → ADP + Pi−30.5Universal energy currency
Glucose-6-phosphate−13.8Low-energy phosphate ester; traps glucose in cells

ATP coupling allows endergonic reactions to proceed by pairing them with ATP hydrolysis so that the net ΔG is negative. Enzymes do not alter ΔG; they lower the activation energy (Ea), increasing reaction rate without shifting equilibrium.

Oxidation-Reduction Reactions

Biological oxidation-reduction (redox) reactions involve electron transfer mediated by coenzymes. NAD+/NADH and FAD/FADH2 are the major electron carriers feeding the ETC. NAD+ accepts two electrons plus a proton (as a hydride ion) to become NADH. FAD accepts two hydrogen atoms to become FADH2. The standard reduction potential (E°′) determines the direction of electron flow: electrons flow from carriers with more negative E°′ (NADH, −0.32 V) toward those with more positive E°′ (O2, +0.82 V), releasing energy captured as the proton gradient.

Shuttle Systems for Cytoplasmic NADH

The inner mitochondrial membrane is impermeable to NADH. Two shuttle systems transfer reducing equivalents from cytoplasmic NADH into the mitochondria. The malate-aspartate shuttle (liver, heart, kidney) regenerates mitochondrial NADH → 2.5 ATP/NADH. The glycerol-3-phosphate shuttle (brain, skeletal muscle) generates mitochondrial FADH2 → 1.5 ATP/NADH. This difference explains why total ATP yield from glucose is quoted as a range (30–32).

ATP Yield Summary

Complete oxidation of one glucose molecule: Glycolysis (2 net ATP + 2 NADH) → Pyruvate dehydrogenase (2 NADH) → TCA cycle (2 GTP + 6 NADH + 2 FADH2) → Oxidative phosphorylation yields approximately 30–32 ATP total (using the malate-aspartate shuttle for cytoplasmic NADH yields 2.5 ATP/NADH; the glycerol-3-phosphate shuttle yields 1.5 ATP/NADH).

04 Amino Acid Classification & Properties

There are 20 standard amino acids encoded by the genetic code, each with a central α-carbon bonded to an amino group, a carboxyl group, a hydrogen atom, and a variable R-group (side chain). All standard amino acids except glycine are L-enantiomers. Amino acids are classified by the chemical properties of their side chains.

Essential Amino Acids

Nine amino acids cannot be synthesized by the human body and must be obtained from the diet: Phe, Val, Thr, Trp, Ile, Met, His, Leu, Lys (mnemonic: PVT TIM HaLL). Histidine is considered conditionally essential (essential in infants, marginally so in adults). Arginine is conditionally essential during growth, pregnancy, and critical illness.

Side Chain Classification

CategoryAmino AcidsKey Properties
Nonpolar, aliphaticGly, Ala, Val, Leu, Ile, ProHydrophobic; found in protein interior; Pro introduces kinks (imino acid)
AromaticPhe, Tyr, TrpUV absorption at 280 nm (Trp strongest); Tyr & Trp fluorescent
Polar, unchargedSer, Thr, Asn, Gln, CysH-bonding; Ser/Thr sites for phosphorylation; Cys forms disulfide bonds
Positively charged (basic)Lys, Arg, HisLys & Arg positive at pH 7.4; His partially protonated (buffer)
Negatively charged (acidic)Asp, GluNegative at pH 7.4; transamination reactions; neurotransmitter (Glu)
Sulfur-containingCys, MetCys: disulfide bonds; Met: methyl donor as SAM, start codon (AUG)

Special Amino Acids

Glycine: smallest AA, achiral, flexible; component of collagen (every 3rd residue), porphyrin synthesis, conjugation reactions. Proline: imino acid with cyclic side chain, disrupts α-helices, introduces rigid kinks; hydroxylated in collagen (requires vitamin C). Selenocysteine: the "21st amino acid," encoded by UGA with a SECIS element; found in glutathione peroxidase and thioredoxin reductase.

Amino Acid Derivatives of Clinical Importance

Amino AcidDerivative(s)Clinical Relevance
TryptophanSerotonin (5-HT), melatonin, niacin (B3), NAD+Carcinoid syndrome: ↑ serotonin → flushing, diarrhea; tryptophan shunted away from niacin → pellagra
TyrosineDopamine, norepinephrine, epinephrine, thyroid hormones (T3/T4), melaninAlbinism: defective tyrosinase → no melanin; Pheochromocytoma: excess catecholamine production
HistidineHistamineAllergic reactions, gastric acid secretion (H2 receptor)
GlutamateGABA (via glutamic acid decarboxylase, requires B6)Seizures in B6 deficiency (decreased GABA synthesis)
GlycinePorphyrins (with succinyl-CoA), glutathione, creatine, bile acid conjugates, purinesHeme synthesis pathway; conjugation of bilirubin
ArginineNitric oxide (via NOS), creatine, ureaEndothelial vasodilation; urea cycle intermediate
MethionineS-adenosylmethionine (SAM) — universal methyl donorSAM methylates DNA, RNA, proteins, phospholipids, neurotransmitters
In the clinical lab, elevated branched-chain amino acids (BCAAs: Val, Ile, Leu) suggest maple syrup urine disease (MSUD), while elevated phenylalanine suggests PKU. Newborn metabolic screens detect these via tandem mass spectrometry.

05 Protein Structure & Folding

Protein function depends entirely on three-dimensional structure. There are four hierarchical levels of protein structure, each stabilized by distinct forces.

Levels of Protein Structure

LevelDescriptionStabilizing ForcesClinical Example
Primary (1°)Linear amino acid sequencePeptide bonds (covalent)Sickle cell disease: Glu6Val in β-globin
Secondary (2°)α-helices, β-sheets, turns, loopsHydrogen bonds (backbone N-H···O=C)α-keratin (hair), β-sheet amyloid (Alzheimer)
Tertiary (3°)Overall 3D shape of single polypeptideHydrophobic interactions, H-bonds, ionic bonds, disulfide bonds, van der WaalsEnzyme active sites; protein misfolding → prion disease
Quaternary (4°)Multi-subunit assemblySame noncovalent forces as tertiaryHemoglobin (α2β2); antibodies

Chaperones & Protein Folding

Chaperones assist in proper protein folding without becoming part of the final structure. Hsp70 binds hydrophobic regions of nascent polypeptides, preventing aggregation. Hsp60 (chaperonins) provide an isolated chamber for folding. Protein disulfide isomerase (PDI) catalyzes correct disulfide bond formation in the ER. Misfolded proteins are tagged with ubiquitin and degraded by the proteasome (ubiquitin-proteasome pathway).

Protein Misfolding Diseases

Prion diseases (CJD, BSE): PrPC (α-helix) misfolds to PrPSc (β-sheet), which is protease-resistant and self-propagating. Amyloidosis: misfolded proteins aggregate into insoluble β-pleated sheet fibrils; stain with Congo red (apple-green birefringence under polarized light). Cystic fibrosis: ΔF508 CFTR misfolding leads to ER retention and degradation.

Post-Translational Modifications

ModificationResidue(s)Function
PhosphorylationSer, Thr, TyrSignal transduction (kinases add, phosphatases remove)
Glycosylation (N-linked)Asn (in Asn-X-Ser/Thr)Begins in ER; protein folding, stability, targeting
Glycosylation (O-linked)Ser, ThrOccurs in Golgi; mucins, blood group antigens
UbiquitinationLysTags proteins for proteasomal degradation
MethylationLys, Arg (histones)Epigenetic regulation of gene expression
AcetylationLys (histones)Histone acetylation opens chromatin (euchromatin)
HydroxylationPro, LysCollagen stabilization (requires vitamin C)
CarboxylationGluγ-carboxylation of clotting factors (requires vitamin K)

06 Hemoglobin & Oxygen Transport

Hemoglobin (Hb) is a tetrameric protein (α2β2 in HbA) that binds up to four O2 molecules with cooperative binding, producing a sigmoidal oxygen-dissociation curve. This cooperativity arises from conformational changes between the tense (T, deoxy, low O2 affinity) and relaxed (R, oxy, high O2 affinity) states. By contrast, myoglobin is a monomer with a hyperbolic binding curve and higher O2 affinity, serving as an intracellular O2 reservoir in muscle.

Oxygen-Dissociation Curve Shifts

FactorRight Shift (decreased affinity → more O2 unloading)Left Shift (increased affinity → less O2 unloading)
pH↓ pH (acidosis) — Bohr effect↑ pH (alkalosis)
CO2↑ CO2↓ CO2
Temperature↑ Temperature↓ Temperature
2,3-BPG↑ 2,3-BPG (altitude, anemia)↓ 2,3-BPG (stored blood)
CO / MetHbCO binding & MetHb shift curve left
Fetal HbHbF has lower 2,3-BPG affinity → left shift

Hemoglobin Variants

HbA2β2): 97% of adult Hb. HbA22δ2): 2–3%; elevated in β-thalassemia trait. HbF2γ2): predominant in fetal life; higher O2 affinity; elevated in sickle cell treated with hydroxyurea. HbS: Glu6Val in β-globin → polymerization when deoxygenated → sickle cells. HbC: Glu6Lys → target cells. HbH4): 3-gene deletion α-thalassemia.

Hemoglobin Pathology Summary

ConditionMutation / DefectKey Features
Sickle cell disease (HbSS)Glu6Val in β-globin (AR)Vaso-occlusive crises, acute chest syndrome, splenic sequestration/autosplenectomy, dactylitis, stroke; Tx: hydroxyurea (↑HbF), transfusions, L-glutamine, voxelotor
Sickle cell trait (HbAS)One copy Glu6ValGenerally asymptomatic; protective against P. falciparum malaria; renal medullary infarcts possible at high altitude
α-ThalassemiaGene deletions (chr 16), 1–4 genes1 gene: silent carrier. 2 genes: trait (microcytic anemia). 3 genes: HbH disease (β4 tetramers). 4 genes: hydrops fetalis (Hb Bart = γ4), fatal in utero
β-Thalassemia minorOne defective β-globin geneMild microcytic anemia, ↑HbA2 (>3.5%), target cells
β-Thalassemia major (Cooley)Both β-globin genes defectiveSevere anemia by 6 months, "crew-cut" skull on X-ray (extramedullary hematopoiesis), hepatosplenomegaly, iron overload from transfusions → secondary hemochromatosis
MethemoglobinemiaOxidized Fe3+ in heme (cannot bind O2)Chocolate-brown blood, cyanosis unresponsive to O2; causes: dapsone, nitrites, benzocaine; Tx: methylene blue (requires G6PD for NADPH)
CO poisoning: CO has ~240x greater affinity for Hb than O2. Pulse oximetry is falsely normal because it cannot distinguish HbCO from HbO2. Diagnosis requires co-oximetry. Treatment: 100% O2 (or hyperbaric O2 for severe cases).

07 Collagen & Connective Tissue Disorders

Collagen is the most abundant protein in the body (~25–35% of total protein). Its hallmark is the triple helix: three left-handed polypeptide chains (each a polyproline II helix) wind around each other in a right-handed super-helix. The repeating sequence is Gly-X-Y, where X is often proline and Y is often hydroxyproline.

Collagen Types

TypeLocationMnemonicAssociated Disease
IBone, skin, tendon, dentin, cornea"Bone" = type IOsteogenesis imperfecta (most forms)
IICartilage, vitreous humor"carTIIlage"Achondrogenesis type II
IIISkin, blood vessels, uterus, GI (reticulin)"three = blood vessels"Ehlers-Danlos (vascular type IV)
IVBasement membrane"4 = floor (BM)"Alport syndrome, Goodpasture syndrome

Collagen Synthesis Steps

Collagen synthesis is a multi-step process spanning multiple cellular compartments:

StepLocationProcessRequirements / Notes
1Nucleus / RERTranscription & translation of preprocollagenSignal peptide directs to ER
2ER lumenHydroxylation of Pro & Lys residuesVitamin C, Fe2+, α-ketoglutarate, O2
3ER lumenGlycosylation of hydroxylysine residuesSpecific galactosyl- and glucosyl-transferases
4ER lumenTriple helix formation (procollagen); disulfide bonds at C-propeptide initiate foldingRequires correct hydroxylation for stability; defective in scurvy
5ExtracellularCleavage of N- and C-terminal propeptides by procollagen peptidases → tropocollagenDefective cleavage in Ehlers-Danlos type VII (dermatosparaxis)
6ExtracellularSelf-assembly into fibrils; covalent cross-linking by lysyl oxidaseRequires Cu2+; defective in Menkes disease (Cu deficiency) and lathyrism (β-aminopropionitrile inhibits lysyl oxidase)
Connective Tissue Disorders

Osteogenesis imperfecta: defective type I collagen → brittle bones, blue sclerae, hearing loss. Ehlers-Danlos syndrome: various collagen/processing defects → hyperextensible skin, joint hypermobility; vascular type (type III collagen) → risk of arterial/organ rupture. Scurvy: vitamin C deficiency → defective hydroxylation → weak collagen → bleeding gums, petechiae, poor wound healing. Menkes disease: X-linked copper transport defect → reduced lysyl oxidase activity → connective tissue laxity, kinky hair.

Elastin & Marfan Syndrome

Elastin is an extracellular matrix protein that provides elastic recoil to tissues such as large arteries, lungs, and ligaments. It is rich in glycine, proline, and hydrophobic amino acids but (unlike collagen) is not glycosylated and has minimal hydroxyproline. Elastin monomers (tropoelastin) are cross-linked by lysyl oxidase (same enzyme as collagen cross-linking, requiring Cu2+) to form desmosine and isodesmosine cross-links unique to elastin. Marfan syndrome (AD, fibrillin-1 gene FBN1 on chromosome 15) affects the microfibrillar scaffold for elastin: tall stature, arachnodactyly, pectus deformities, upward lens subluxation, mitral valve prolapse, aortic root dilation (risk of dissection). α-1-Antitrypsin deficiency leads to unopposed elastase activity in the lungs → panacinar emphysema (lower lobes); associated with liver disease (PAS-positive, diastase-resistant globules in hepatocytes).

08 Enzyme Kinetics & Inhibition

Enzymes are biological catalysts that increase reaction rates by lowering activation energy without being consumed. Most are proteins; some are RNA (ribozymes). The active site binds substrate with specificity described by the lock-and-key model (Fischer) or the induced-fit model (Koshland). Enzyme kinetics follows the Michaelis-Menten equation: V = Vmax[S] / (Km + [S]).

Key Kinetic Parameters

ParameterDefinitionClinical Significance
KmSubstrate concentration at ½ VmaxReflects enzyme-substrate affinity (low Km = high affinity)
VmaxMaximum reaction velocityProportional to enzyme concentration [ET]
kcatTurnover number (Vmax/[ET])Catalytic efficiency of a single enzyme molecule
kcat/KmCatalytic efficiency (specificity constant)Best measure of overall enzyme efficiency

Types of Enzyme Inhibition

TypeBinds ToEffect on KmEffect on VmaxLineweaver-BurkExample
CompetitiveActive site (competes with S)↑ (apparent)UnchangedLines intersect on y-axisMethotrexate vs. folate (DHFR)
UncompetitiveES complex only↓ (apparent)Parallel linesLithium on IMPase
NoncompetitiveAllosteric site (E or ES)UnchangedLines intersect on x-axisHeavy metals on various enzymes
MixedAllosteric site (E or ES, different affinity)Changed (up or down)Lines intersect in quadrant II or IIIMany drug-enzyme interactions
Lineweaver-Burk Plot

The double-reciprocal plot (1/V vs. 1/[S]) linearizes Michaelis-Menten kinetics. Y-intercept = 1/Vmax; X-intercept = −1/Km; Slope = Km/Vmax. Competitive inhibitors increase the x-intercept magnitude (higher apparent Km) while preserving the y-intercept (same Vmax). Overcoming competitive inhibition requires increasing [S].

Cooperative Kinetics & Allosteric Enzymes

Allosteric enzymes do not follow Michaelis-Menten kinetics. They display a sigmoidal (S-shaped) velocity curve rather than a hyperbolic one, reflecting cooperative substrate binding among multiple subunits. The Hill coefficient (nH) quantifies cooperativity: nH > 1 = positive cooperativity (e.g., hemoglobin, nH ≈ 2.8); nH = 1 = no cooperativity (Michaelis-Menten); nH < 1 = negative cooperativity.

Allosteric activators stabilize the R (relaxed) state, shifting the curve left (lower K0.5, increased apparent affinity). Allosteric inhibitors stabilize the T (tense) state, shifting the curve right (higher K0.5, decreased apparent affinity). The classic example is PFK-1: ATP acts as both a substrate and an allosteric inhibitor at a separate regulatory site, while AMP and fructose-2,6-bisphosphate are potent allosteric activators.

Enzyme Classification (EC Numbers)

ClassReaction CatalyzedExample
1. OxidoreductasesElectron transfer (oxidation/reduction)Lactate dehydrogenase, cytochrome c oxidase
2. TransferasesTransfer functional groups between moleculesKinases (phosphoryl transfer), transaminases (amino group)
3. HydrolasesHydrolysis (break bonds using water)Lipases, proteases, phosphatases, esterases
4. LyasesNon-hydrolytic bond cleavage (or form double bonds)Aldolase, decarboxylases, dehydratases
5. IsomerasesIntramolecular rearrangementPhosphoglucose isomerase, racemases, mutases
6. Ligases (synthetases)Bond formation coupled to ATP hydrolysisDNA ligase, glutamine synthetase, acetyl-CoA carboxylase
Statin drugs are competitive inhibitors of HMG-CoA reductase (the rate-limiting enzyme in cholesterol synthesis). Their structural similarity to HMG-CoA allows them to compete for the active site, reducing hepatic cholesterol production.

09 Enzyme Regulation & Clinical Enzymology

Enzyme activity is regulated at multiple levels to maintain metabolic homeostasis.

Mechanisms of Enzyme Regulation

MechanismDescriptionExample
Allosteric regulationEffector binding at a site other than the active site changes enzyme conformationPFK-1: activated by AMP, fructose-2,6-BP; inhibited by ATP, citrate
Covalent modificationPhosphorylation, acetylation, etc.Glycogen phosphorylase: active when phosphorylated (phosphorylase a)
Proteolytic cleavageIrreversible activation of zymogensTrypsinogen → trypsin; prothrombin → thrombin
Transcriptional controlInduction or repression of enzyme synthesisGlucokinase induced by insulin; PEPCK induced by cortisol/glucagon
CompartmentalizationSeparation of opposing pathwaysFatty acid synthesis (cytoplasm) vs. β-oxidation (mitochondria)

Clinically Important Serum Enzymes

EnzymeSource TissueClinical Use
AST (SGOT)Heart, liver, muscleMI, hepatitis; found in mitochondria + cytoplasm
ALT (SGPT)Liver (most specific)Hepatocellular injury; more liver-specific than AST
Alkaline phosphatase (ALP)Bone, liver, placentaObstructive liver disease, bone disease (Paget)
GGTLiver, biliaryBiliary disease, alcohol use; confirms hepatic origin of ↑ALP
Amylase / LipasePancreas, salivaryAcute pancreatitis (lipase more specific & remains elevated longer)
Troponin I/THeartMost specific and sensitive marker for MI
CK-MBHeartReinfarction detection (rises & falls faster than troponin)
LDHUbiquitousLDH-1 > LDH-2 in MI ("flipped ratio"); tissue ischemia/necrosis

Isoenzymes & Isozymes

Isozymes (isoenzymes) are different molecular forms of the same enzyme that catalyze the same reaction but differ in kinetic properties, tissue distribution, and electrophoretic mobility. Clinically important examples:

EnzymeIsozymesClinical Significance
Lactate dehydrogenase (LDH)LDH-1 (HHHH, heart), LDH-2 (HHHM), LDH-3, LDH-4, LDH-5 (MMMM, liver/muscle)LDH-1 > LDH-2 = "flipped ratio" in MI; LDH-5 elevated in liver disease
Creatine kinase (CK)CK-MM (muscle), CK-MB (heart), CK-BB (brain)CK-MB elevation in MI (>5% of total CK); CK-MM in rhabdomyolysis
Alkaline phosphatase (ALP)Bone, liver, intestinal, placental (Regan isozyme in cancer)Isoform analysis distinguishes bone vs. liver source of elevation

Enzyme Defects & Drug Metabolism

The cytochrome P450 family (particularly CYP3A4, CYP2D6, CYP2C19, CYP2C9) is responsible for phase I drug metabolism in the liver. Genetic polymorphisms cause variable drug metabolism: poor metabolizers (e.g., CYP2D6 poor metabolizers cannot activate codeine to morphine) and ultra-rapid metabolizers (excessive activation → toxicity). CYP inducers (rifampin, carbamazepine, phenobarbital, phenytoin, St. John's wort) increase drug clearance. CYP inhibitors (azole antifungals, macrolides, grapefruit juice, cimetidine, ritonavir) decrease drug clearance → toxicity risk.

Phase I vs. Phase II Drug Metabolism

Phase I (functionalization): cytochrome P450 enzymes introduce or expose a functional group (oxidation, reduction, hydrolysis) → often produces a more reactive metabolite. Phase II (conjugation): transferase enzymes attach a polar group (glucuronide, sulfate, acetyl, glutathione, glycine, methyl) → increases water solubility for renal/biliary excretion. Example: acetaminophen is conjugated (phase II) under normal conditions, but CYP2E1 (phase I) generates the toxic metabolite NAPQI, which is detoxified by glutathione conjugation. Overdose depletes glutathione → NAPQI causes hepatic necrosis. Treatment: N-acetylcysteine (replenishes glutathione).

In suspected MI, troponin I or T is the gold standard biomarker. It begins to rise 3–6 hours post-infarct, peaks at 12–24 hours, and remains elevated for 7–10 days. CK-MB rises and falls more rapidly, making it useful for detecting reinfarction within that window.

10 Glycolysis & Pyruvate Metabolism

Glycolysis is the 10-step cytoplasmic pathway that converts one molecule of glucose into two molecules of pyruvate, generating 2 net ATP (by substrate-level phosphorylation) and 2 NADH. It is the central metabolic pathway used by all cells and the only source of ATP in cells lacking mitochondria (e.g., mature RBCs).

Key Regulatory Steps of Glycolysis

StepEnzymeReactionRegulation
1Hexokinase (or Glucokinase in liver)Glucose → G6PHexokinase: inhibited by G6P; Glucokinase: induced by insulin, high Km, not inhibited by G6P
3PFK-1 (rate-limiting)F6P → F1,6BPActivated by AMP, fructose-2,6-BP; Inhibited by ATP, citrate
10Pyruvate kinasePEP → PyruvateActivated by F1,6BP (feedforward); Inhibited by ATP, alanine; phosphorylated (inactivated) by glucagon

Fates of Pyruvate

Aerobic: Pyruvate enters mitochondria → pyruvate dehydrogenase complex (PDH) converts it to acetyl-CoA + CO2 + NADH. PDH requires 5 cofactors: thiamine (B1), lipoic acid, CoA (from B5), FAD (from B2), NAD+ (from B3) (mnemonic: Tender Loving Care For Nancy). Anaerobic: Lactate dehydrogenase (LDH) converts pyruvate to lactate, regenerating NAD+ to sustain glycolysis. Transamination: Pyruvate → alanine (ALT reaction). Carboxylation: Pyruvate carboxylase converts pyruvate to oxaloacetate (gluconeogenesis entry, TCA anaplerosis).

Glucokinase vs. Hexokinase

FeatureHexokinase (I–III)Glucokinase (Hexokinase IV)
LocationMost tissuesLiver, pancreatic β-cells
Km for glucoseLow (~0.1 mM) → always active at physiological glucoseHigh (~10 mM) → active only when glucose is elevated (fed state)
VmaxLowHigh (high capacity for glucose clearance)
Product inhibitionInhibited by G6PNOT inhibited by G6P
InductionConstitutiveInduced by insulin
Clinical significanceTraps glucose in cells at all glucose levels"Glucose sensor" in β-cells (triggers insulin secretion); MODY-2 = glucokinase mutation

Warburg Effect

Cancer cells preferentially utilize glycolysis even in the presence of adequate O2 (aerobic glycolysis). This metabolic reprogramming supports rapid biosynthesis of nucleotides, amino acids, and lipids needed for proliferation. The Warburg effect is the basis for FDG-PET scanning in oncology: tumor cells have increased glucose uptake (via GLUT1 upregulation), and 18F-fluorodeoxyglucose accumulates because it is phosphorylated by hexokinase but cannot proceed further through glycolysis.

Pyruvate Dehydrogenase Deficiency

X-linked deficiency of E1 subunit of PDH causes lactic acidosis, neurological defects, and elevated serum alanine. Cannot convert pyruvate to acetyl-CoA, so pyruvate is shunted to lactate and alanine. Treatment: ketogenic diet (provides acetyl-CoA from fat), thiamine supplementation. Note: arsenic poisoning mimics this by inhibiting lipoic acid-containing enzymes (PDH, α-ketoglutarate dehydrogenase).

11 TCA Cycle & Oxidative Phosphorylation

The tricarboxylic acid (TCA/Krebs/citric acid) cycle occurs in the mitochondrial matrix. Acetyl-CoA condenses with oxaloacetate to form citrate, and through 8 enzymatic steps regenerates oxaloacetate while producing 3 NADH, 1 FADH2, and 1 GTP per turn. Two turns occur per glucose molecule.

TCA Cycle: Key Enzymes & Products

EnzymeReactionProduct(s)Notes
Citrate synthaseOAA + Acetyl-CoA → CitrateCitrateInhibited by ATP, citrate, succinyl-CoA
Isocitrate dehydrogenaseIsocitrate → α-ketoglutarateNADH, CO2Rate-limiting step; activated by ADP; inhibited by ATP, NADH
α-Ketoglutarate dehydrogenaseα-KG → Succinyl-CoANADH, CO2Same cofactors as PDH (B1, lipoate, CoA, FAD, NAD+); inhibited by succinyl-CoA, NADH
Succinyl-CoA synthetaseSuccinyl-CoA → SuccinateGTP (substrate-level phosphorylation)Only substrate-level phosphorylation in cycle
Succinate dehydrogenaseSuccinate → FumarateFADH2Only enzyme embedded in inner mitochondrial membrane (Complex II of ETC)
Malate dehydrogenaseMalate → OAANADHRegenerates OAA to continue cycle

Electron Transport Chain & Oxidative Phosphorylation

The ETC comprises four complexes (I–IV) embedded in the inner mitochondrial membrane, plus mobile carriers (ubiquinone/CoQ, cytochrome c). NADH donates electrons at Complex I (NADH dehydrogenase); FADH2 donates at Complex II (succinate dehydrogenase). Electrons flow through Complex III (cytochrome bc1) and Complex IV (cytochrome c oxidase) to O2, reducing it to H2O. Proton pumping at Complexes I, III, and IV creates the electrochemical gradient. ATP synthase (Complex V) uses this gradient to synthesize ATP from ADP + Pi.

ETC Inhibitors & Uncouplers

AgentTargetEffect
Rotenone, barbiturates, piericidin AComplex IBlock NADH → CoQ electron transfer
Antimycin AComplex IIIBlocks CoQ → cytochrome c transfer
Cyanide, CO, H2SComplex IVBlock electron transfer to O2; lethal (histotoxic hypoxia)
OligomycinATP synthase (Fo subunit)Blocks proton channel; stops ATP synthesis and ETC backlog
2,4-DNP, thermogenin (UCP1)Inner membraneUncouple: protons leak across membrane → ↑ O2 consumption, ↓ ATP, ↑ heat

Anaplerotic Reactions

TCA cycle intermediates are drained off for biosynthesis (e.g., citrate for fatty acid synthesis, α-KG for amino acid synthesis, succinyl-CoA for heme synthesis, OAA for gluconeogenesis). Anaplerotic reactions replenish these intermediates: the most important is pyruvate carboxylase (pyruvate + CO2 → OAA; activated by acetyl-CoA, requires biotin). Others include glutamate dehydrogenase (α-KG ↔ glutamate) and propionyl-CoA pathway (odd-chain fatty acids and some amino acids → succinyl-CoA via methylmalonyl-CoA mutase, requiring B12).

Mitochondrial Membrane Transport

The inner mitochondrial membrane is highly selective. Key transport systems: Citrate shuttle: exports citrate to cytoplasm for fatty acid synthesis (citrate is cleaved by ATP-citrate lyase to OAA + acetyl-CoA). Malate-aspartate shuttle: transfers NADH equivalents (see bioenergetics section). Carnitine shuttle: imports long-chain fatty acids for β-oxidation. Adenine nucleotide translocase (ANT): exchanges ATP (out) for ADP (in); inhibited by atractyloside.

Cyanide poisoning presents with altered mental status, seizures, lactic acidosis, and the classic "bitter almond" odor. The antidote kit uses nitrites (to form methemoglobin, which binds CN) and thiosulfate (rhodanese converts CN to thiocyanate for renal excretion). Newer treatment: hydroxocobalamin (Cyanokit) directly binds CN.

12 Gluconeogenesis & Glycogen Metabolism

Gluconeogenesis generates glucose from non-carbohydrate precursors (lactate, glycerol, glucogenic amino acids, propionyl-CoA) primarily in the liver and to a lesser extent the kidney cortex. It is essentially the reverse of glycolysis except at three irreversible steps, which are bypassed by different enzymes.

Gluconeogenesis Bypass Enzymes

Glycolysis EnzymeGluconeogenesis BypassLocationRegulation
Pyruvate kinasePyruvate carboxylase (PYR → OAA) then PEPCK (OAA → PEP)Mitochondria (PC) / Cytoplasm (PEPCK)PC: activated by acetyl-CoA; PEPCK: induced by cortisol, glucagon
PFK-1Fructose-1,6-bisphosphataseCytoplasmInhibited by AMP, fructose-2,6-BP; Activated by citrate
Hexokinase/GlucokinaseGlucose-6-phosphataseER membrane (liver, kidney only)Deficiency: von Gierke disease (GSD type I)

Glycogen Metabolism

Glycogen Structure & Enzymes

Glycogen is a highly branched polymer of glucose with α-1,4 glycosidic bonds (linear chains) and α-1,6 glycosidic bonds (branch points, every 8–12 residues). The extensive branching creates many non-reducing ends, allowing rapid simultaneous glucose release by multiple glycogen phosphorylase molecules—critical for the rapid mobilization of glucose during exercise or the fight-or-flight response.

Glycogenesis (synthesis): Glycogenin serves as a primer (auto-glucosylating protein). Glycogen synthase (rate-limiting) adds UDP-glucose to the non-reducing end in α-1,4 linkages. Branching enzyme transfers a block of ~7 residues to create α-1,6 branch points. Glycogenolysis (breakdown): Glycogen phosphorylase (rate-limiting) cleaves α-1,4 bonds from non-reducing ends, releasing glucose-1-phosphate. Debranching enzyme has dual activity: transferase (moves 3 residues) + α-1,6-glucosidase (cleaves the branch point, releasing free glucose). In liver, G1P → G6P → free glucose (via glucose-6-phosphatase) for blood glucose maintenance; in muscle, G6P enters glycolysis directly (muscle lacks G6Pase and therefore cannot export glucose).

Hormonal Regulation of Glycogen Metabolism

Insulin (fed state): activates glycogen synthase (via protein phosphatase 1), inhibits glycogen phosphorylase. Glucagon (fasting, liver): activates adenylate cyclase → cAMP → PKA → phosphorylase kinase → glycogen phosphorylase a (active). Epinephrine (muscle & liver): same cAMP-PKA cascade in liver; in muscle also via IP3 → Ca2+ → calmodulin → phosphorylase kinase activation.

Fructose-2,6-Bisphosphate: The Master Metabolic Switch

Fructose-2,6-bisphosphate (F2,6BP) is the most potent allosteric activator of PFK-1 (glycolysis) and inhibitor of fructose-1,6-bisphosphatase (gluconeogenesis). It is produced by phosphofructokinase-2 (PFK-2) and degraded by fructose-bisphosphatase-2 (FBPase-2)—both activities reside on the same bifunctional enzyme. In the fed state, insulin activates a phosphatase that dephosphorylates PFK-2/FBPase-2, promoting PFK-2 activity → ↑F2,6BP → glycolysis favored. In the fasted state, glucagon activates PKA which phosphorylates the enzyme, promoting FBPase-2 activity → ↓F2,6BP → gluconeogenesis favored.

Cori Cycle & Alanine Cycle

The Cori cycle transfers the metabolic burden of lactate recycling from muscle to liver: muscle glycolysis produces lactate → lactate travels to liver → liver converts lactate back to glucose via gluconeogenesis → glucose returns to muscle. The alanine (glucose-alanine) cycle is analogous: muscle transamination produces alanine from pyruvate → alanine travels to liver → liver converts alanine to pyruvate (then to glucose) and channels the amino group into the urea cycle. Both cycles are critical during exercise and fasting.

13 Glycogen Storage Diseases

The glycogen storage diseases (GSDs) are inherited enzyme deficiencies that lead to abnormal glycogen accumulation or impaired glycogen mobilization. They classically present with hepatomegaly, hypoglycemia, or myopathy depending on the tissue affected.

TypeNameDeficient EnzymeKey Features
IVon GierkeGlucose-6-phosphataseSevere fasting hypoglycemia, hepatomegaly, lactic acidosis, hyperuricemia, hyperlipidemia; liver & kidney affected
IIPompeAcid maltase (α-1,4-glucosidase, lysosomal)Cardiomegaly (infantile form), hypotonia, macroglossia; "pomPe = Pump (heart)"; lysosomal disease
IIICori (Forbes)Debranching enzyme (α-1,6-glucosidase)Milder form of von Gierke; short outer chains on glycogen; liver & muscle affected
IVAndersenBranching enzymeLong, unbranched glycogen (amylopectin-like) → cirrhosis, hepatic failure; fatal in infancy without transplant
VMcArdleMuscle glycogen phosphorylaseExercise intolerance, myoglobinuria, painful cramps; "McArdle = Muscle"; no rise in blood lactate with exercise (ischemic forearm test)

Additional Glycogen Storage Diseases

TypeNameDeficient EnzymeKey Features
VIHersHepatic glycogen phosphorylaseMild hepatomegaly, mild hypoglycemia; benign course; "Hers = Hepatic"
VIITaruiMuscle PFK-1Exercise intolerance similar to McArdle; hemolytic anemia (PFK-1 also in RBCs)
IXPhosphorylase kinaseMost common GSD overall; X-linked or AR forms; hepatomegaly, mild hypoglycemia, growth delay; excellent prognosis
GSD Diagnostic Approach

GSDs presenting primarily with hepatomegaly & hypoglycemia: von Gierke (I), Cori (III), Hers (VI), phosphorylase kinase deficiency (IX). GSDs presenting primarily with myopathy: McArdle (V), Tarui (VII). Pompe (II) is unique: it is a lysosomal storage disease (acid maltase) causing cardiomyopathy and skeletal myopathy. Key lab differentiators: von Gierke has lactic acidosis, hyperuricemia, and hyperlipidemia (the others do not to the same degree).

The ischemic forearm test is used for McArdle disease (type V): the patient exercises with a blood pressure cuff above systolic → normal patients show rising lactate; McArdle patients show no lactate rise (cannot break down muscle glycogen) but have exaggerated ammonia rise.

14 Pentose Phosphate Pathway & G6PD Deficiency

The pentose phosphate pathway (PPP/HMP shunt) occurs in the cytoplasm and has two phases. The oxidative phase is irreversible and generates NADPH (for reductive biosynthesis and glutathione reduction) and ribulose-5-phosphate. The non-oxidative phase is reversible, interconverting sugars and connecting to glycolysis (via fructose-6-phosphate and glyceraldehyde-3-phosphate). The rate-limiting enzyme is glucose-6-phosphate dehydrogenase (G6PD).

Pentose Phosphate Pathway — Two Phases

The oxidative phase is irreversible and consists of three reactions: (1) G6PD oxidizes G6P to 6-phosphoglucono-δ-lactone (producing the first NADPH). (2) Lactonase hydrolyzes the lactone to 6-phosphogluconate. (3) 6-Phosphogluconate dehydrogenase oxidizes and decarboxylates to ribulose-5-phosphate (producing the second NADPH + CO2). Net per G6P entering: 2 NADPH + 1 ribulose-5-phosphate + 1 CO2.

The non-oxidative phase is reversible and uses transketolase (requires TPP/B1) and transaldolase to interconvert C3, C4, C5, C6, and C7 sugars. This connects the PPP to glycolysis: it can generate ribose-5-phosphate for nucleotide synthesis when needed, or funnel excess pentose phosphates back into glycolysis (as F6P and G3P) when NADPH demand exceeds ribose demand. Tissues with high NADPH demand (liver, adrenal cortex, RBCs, lactating mammary gland, adipose) have particularly active PPP.

Functions of NADPH

ProcessNADPH RoleClinical Significance
Glutathione reductionGlutathione reductase uses NADPH to regenerate reduced glutathione (GSH)GSH detoxifies H2O2 in RBCs; deficiency → oxidative hemolysis
Fatty acid synthesisReductive biosynthesisLipogenesis in liver, adipose, lactating mammary gland
Cholesterol synthesisHMG-CoA reductase uses NADPHTarget of statins
Steroid synthesisCytochrome P450 reactionsAdrenal steroidogenesis
Respiratory burstNADPH oxidase generates superoxide (O2)Defective in chronic granulomatous disease (CGD)
Nitric oxide synthesisNOS requires NADPHEndothelial vasodilation

G6PD Deficiency

G6PD deficiency is the most common enzyme deficiency worldwide (X-linked recessive, protective against P. falciparum malaria). Reduced NADPH production leads to inability to maintain reduced glutathione in RBCs → oxidative damage to hemoglobin → Heinz bodies (denatured Hb precipitates) and bite cells (splenic macrophage removal of Heinz bodies). Episodes are triggered by oxidant stresses: fava beans, infections, sulfonamides, primaquine, dapsone, nitrofurantoin.

G6PD Deficiency Variants

VariantPopulationEnzyme ActivityClinical Severity
G6PD B (wild type)Most populationsNormal (100%)None
G6PD A+ (normal variant)African descent85–100%None
G6PD A−African descent (10–15%)5–15%Mild/moderate episodic hemolysis; self-limited (older RBCs destroyed, reticulocytes have adequate enzyme)
G6PD MediterraneanMediterranean, Middle Eastern<1%Severe; hemolysis can be life-threatening; all RBC ages affected; favism (fava beans)

Oxidant Stressors Triggering G6PD Hemolysis

Common triggers include: Infections (most common precipitant overall), fava beans (contain vicine/divicine), medications (primaquine, dapsone, sulfonamides, nitrofurantoin, rasburicase, methylene blue), and metabolic acidosis (DKA). Methylene blue is both a cause (oxidant in excess) and a treatment for methemoglobinemia (requires NADPH from G6PD to reduce MetHb), meaning methylene blue is contraindicated in G6PD-deficient patients with methemoglobinemia—use ascorbic acid instead.

G6PD deficiency produces episodic hemolytic anemia following oxidant stress. Diagnosis: quantitative G6PD enzyme assay (note: levels may be falsely normal during acute hemolysis because reticulocytes have higher G6PD activity; retest after recovery). Peripheral smear: bite cells, Heinz bodies (supravital stain).

15 Fructose & Galactose Metabolism

Fructose and galactose are dietary sugars that enter glycolysis after conversion to glycolytic intermediates. Defects in these pathways cause distinct clinical syndromes.

Fructose Metabolism Disorders

ConditionDeficient EnzymeAccumulated SubstrateClinical Features
Essential fructosuriaFructokinaseFructose (in blood & urine)Benign; asymptomatic; incidental finding
Hereditary fructose intoleranceAldolase BFructose-1-phosphateHypoglycemia, jaundice, vomiting after fructose/sucrose ingestion; F1P inhibits glycogenolysis & gluconeogenesis; traps phosphate → ↓ATP

Galactose Metabolism Disorders

ConditionDeficient EnzymeAccumulated SubstrateClinical Features
Galactokinase deficiencyGalactokinaseGalactitolInfantile cataracts (galactitol osmotic damage); relatively mild
Classic galactosemiaGalactose-1-phosphate uridylyltransferaseGalactose-1-phosphate, galactitolFailure to thrive, jaundice, hepatomegaly, infantile cataracts, intellectual disability, E. coli sepsis in neonates; treatment: eliminate galactose & lactose from diet
Pathway Logic

Both fructose and galactose disorders illustrate a common biochemical principle: when an enzyme in a pathway is deficient, its substrate accumulates and is shunted into alternative pathways (e.g., aldose reductase converts galactose to galactitol, which accumulates in the lens causing cataracts). This "upstream backup and side-shunt" pattern recurs throughout metabolic disease.

Sorbitol (Polyol) Pathway

In tissues that do not require insulin for glucose uptake (lens, retina, kidneys, Schwann cells), chronically elevated glucose is converted to sorbitol by aldose reductase (using NADPH) and then to fructose by sorbitol dehydrogenase (using NAD+). Because sorbitol cannot cross cell membranes, it accumulates intracellularly, causing osmotic damage. This mechanism contributes to diabetic complications: cataracts (lens), retinopathy (retina), peripheral neuropathy (Schwann cells), and nephropathy (kidney). Aldose reductase inhibitors have been explored therapeutically but have limited clinical success to date.

Lactose Intolerance

Lactase is a brush border enzyme in small intestinal villi that cleaves lactose into glucose + galactose. Lactase deficiency (primary: age-related downregulation, most common worldwide; secondary: mucosal injury from celiac disease, infectious enteritis, etc.) leads to undigested lactose reaching the colon → bacterial fermentation → bloating, flatulence, osmotic diarrhea, abdominal cramps. Diagnosis: hydrogen breath test (colonic bacteria metabolize lactose producing H2). Treatment: dietary lactose restriction, oral lactase supplements.

Other Disaccharidase Deficiencies

In addition to lactase, the brush border contains sucrase-isomaltase (cleaves sucrose into glucose + fructose, and isomaltose at α-1,6 branch points) and trehalase (cleaves trehalose from mushrooms). Congenital sucrase-isomaltase deficiency presents in infancy with osmotic diarrhea upon introduction of sucrose-containing foods (fruits, juice, table sugar). Secondary disaccharidase deficiency can accompany any condition damaging the intestinal brush border (viral gastroenteritis, celiac disease, Crohn disease, tropical sprue). After mucosal recovery, disaccharidase activity typically returns, but lactase is the slowest to recover and may remain persistently low.

16 Fatty Acid Synthesis & Beta-Oxidation

Fatty acid synthesis and β-oxidation are reciprocally regulated pathways that occur in different cellular compartments.

Fatty Acid Synthesis vs. Beta-Oxidation

FeatureSynthesisβ-Oxidation
LocationCytoplasmMitochondrial matrix
CarrierACP (acyl carrier protein)CoA
Key enzymeAcetyl-CoA carboxylase (ACC) — rate-limitingCarnitine palmitoyltransferase I (CPT-I) — rate-limiting
Carbon unitsAdds 2C per cycle (from malonyl-CoA)Removes 2C per cycle (as acetyl-CoA)
Reducing agentNADPH (from PPP, malic enzyme)Produces NADH & FADH2
Activated byInsulin, citrateGlucagon, epinephrine
Inhibited byGlucagon (phosphorylation of ACC), palmitoyl-CoAMalonyl-CoA (inhibits CPT-I)

Carnitine Shuttle

Long-chain fatty acids cannot cross the inner mitochondrial membrane directly. The carnitine shuttle is a three-step process:

StepEnzyme / TransporterLocationReaction
1CPT-I (carnitine palmitoyltransferase I)Outer mitochondrial membraneAcyl-CoA + carnitine → acylcarnitine + CoA
2Carnitine-acylcarnitine translocaseInner mitochondrial membraneAcylcarnitine enters; free carnitine exits
3CPT-II (carnitine palmitoyltransferase II)Inner mitochondrial membrane (matrix side)Acylcarnitine + CoA → acyl-CoA + carnitine

CPT-I is the rate-limiting step and the key regulatory point: it is allosterically inhibited by malonyl-CoA (the first committed intermediate in fatty acid synthesis). This ensures that synthesis and oxidation do not occur simultaneously. Medium-chain fatty acids (C6–C12) bypass the carnitine shuttle entirely, entering the mitochondrial matrix by diffusion.

Fatty Acid Oxidation Disorders

Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is the most common fatty acid oxidation defect. Presents in infancy with hypoketotic hypoglycemia, vomiting, lethargy, and liver dysfunction after fasting. Elevated medium-chain acylcarnitines on newborn screen. Avoid fasting; frequent feeding. Systemic carnitine deficiency presents similarly; treatment: oral carnitine supplementation.

Odd-Chain & Very-Long-Chain Fatty Acid Oxidation

Odd-chain fatty acids (e.g., C15, C17, found in dairy and ruminant fat) undergo β-oxidation normally until the final 3-carbon unit, propionyl-CoA. Propionyl-CoA carboxylase (requires biotin) converts it to D-methylmalonyl-CoA, which is racemized and then converted to succinyl-CoA by methylmalonyl-CoA mutase (requires B12). Succinyl-CoA enters the TCA cycle. B12 deficiency thus causes elevated methylmalonic acid.

Very-long-chain fatty acids (VLCFAs, ≥C22) are first shortened in peroxisomes (via peroxisomal β-oxidation), then transferred to mitochondria for completion. Zellweger syndrome: absent peroxisomes (peroxisome biogenesis disorder) → VLCFA accumulation, hypotonia, seizures, hepatomegaly, characteristic facies; fatal in infancy. X-linked adrenoleukodystrophy: defective peroxisomal VLCFA transporter (ABCD1) → VLCFA accumulation in adrenal cortex and CNS white matter → adrenal insufficiency, progressive demyelination.

The hallmark of fatty acid oxidation defects is hypoketotic hypoglycemia—the body cannot make ketones from fat during fasting, and gluconeogenesis fails because acetyl-CoA (a gluconeogenesis activator via pyruvate carboxylase) is insufficient. This distinguishes FAO defects from ketotic causes of hypoglycemia.

17 Ketogenesis & Ketolysis

Ketogenesis occurs in liver mitochondria during prolonged fasting, starvation, or uncontrolled diabetes when acetyl-CoA production (from β-oxidation) exceeds TCA cycle capacity. The three ketone bodies are acetoacetate, β-hydroxybutyrate (the predominant circulating form), and acetone (volatile, exhaled → fruity breath).

Ketogenesis Pathway

2 Acetyl-CoA → acetoacetyl-CoA (thiolase) → HMG-CoA (HMG-CoA synthase, rate-limiting) → acetoacetate + acetyl-CoA (HMG-CoA lyase). Acetoacetate is reduced to β-hydroxybutyrate by β-hydroxybutyrate dehydrogenase (using NADH), or spontaneously decarboxylated to acetone.

Ketolysis (Peripheral Utilization)

Extrahepatic tissues (brain, heart, skeletal muscle, kidney) convert β-hydroxybutyrate back to acetoacetate, then to acetoacetyl-CoA via succinyl-CoA-acetoacetate CoA transferase (thiophorase), and finally to 2 acetyl-CoA for the TCA cycle. The liver cannot use ketone bodies because it lacks thiophorase.

Diabetic Ketoacidosis (DKA)

Uncontrolled type 1 diabetes → absolute insulin deficiency → unopposed lipolysis → massive β-oxidation → excess acetyl-CoA → ketone body overproduction. Accumulation of acetoacetate and β-hydroxybutyrate causes high-anion-gap metabolic acidosis. Presentation: Kussmaul breathing (compensatory hyperventilation), fruity breath (acetone), abdominal pain, dehydration. Lab: high glucose, high anion gap, low bicarbonate, positive serum ketones. Treatment: IV fluids, insulin, potassium replacement, monitoring.

Alcoholic Ketoacidosis (AKA)

Chronic alcohol use combined with poor nutrition and recent binge → depleted glycogen stores + ↑NADH/NAD+ ratio (from ethanol metabolism) → impaired gluconeogenesis + enhanced lipolysis and ketogenesis. Unlike DKA, glucose is typically low or normal (not elevated). Labs show high anion gap metabolic acidosis with positive ketones. β-Hydroxybutyrate predominates (high NADH shifts acetoacetate → β-HB), so the nitroprusside test (detects only acetoacetate) may be falsely negative initially. Treatment: IV fluids with dextrose (D5NS), thiamine before glucose (to prevent Wernicke encephalopathy), electrolyte replacement.

Starvation Ketosis

During prolonged fasting (>48–72 hours), hepatic glycogen is exhausted and gluconeogenesis alone cannot meet glucose demands. The liver increases ketogenesis from fatty acids. Ketone bodies (particularly β-hydroxybutyrate) become the brain's major fuel source, reducing the need for gluconeogenesis and thereby sparing muscle protein. In simple starvation, the degree of ketoacidosis is milder than in DKA because basal insulin secretion is preserved, limiting lipolysis to a controlled rate.

18 Lipoproteins & Cholesterol Metabolism

Lipids are transported in blood as lipoproteins—spherical particles with a hydrophobic core (triglycerides, cholesterol esters) and an amphipathic shell (phospholipids, free cholesterol, apolipoproteins).

Lipoprotein Classes

LipoproteinSourceMajor LipidKey ApolipoproteinFunction
ChylomicronsIntestineDietary TGsApoB-48, ApoC-II, ApoEDeliver dietary TGs to peripheral tissues
VLDLLiverHepatic TGsApoB-100, ApoC-II, ApoEDeliver endogenous TGs to peripheral tissues
IDLVLDL remnantTGs + cholesterolApoB-100, ApoEIntermediate; converted to LDL or taken up by liver
LDLIDL conversionCholesterolApoB-100Delivers cholesterol to tissues; "bad cholesterol"
HDLLiver, intestineCholesterol estersApoA-I, ApoC-II, ApoEReverse cholesterol transport; "good cholesterol"

Key Enzymes & Receptors

Lipoprotein lipase (LPL): on capillary endothelium; activated by ApoC-II; hydrolyzes TGs in chylomicrons and VLDL. Hepatic lipase: converts IDL to LDL. LCAT (lecithin-cholesterol acyltransferase): esterifies cholesterol on HDL; activated by ApoA-I. CETP (cholesterol ester transfer protein): transfers cholesterol esters from HDL to LDL/VLDL in exchange for TGs. LDL receptor: hepatic uptake of LDL; recognizes ApoB-100 and ApoE.

Dyslipidemias

ConditionDefectLipid ProfileClinical Features
Familial hypercholesterolemia (type IIa)LDL receptor deficiency (AD)↑↑↑ LDLXanthomas (tendon), xanthelasma, corneal arcus, early MI
Familial hypertriglyceridemia (type I)LPL or ApoC-II deficiency↑↑↑ TGs, ↑ chylomicronsPancreatitis, eruptive xanthomas, lipemia retinalis, creamy supernatant
Familial dysbetalipoproteinemia (type III)ApoE2/E2 homozygosity↑ TGs, ↑ cholesterol, ↑ IDLPalmar xanthomas, tuberoeruptive xanthomas
AbetalipoproteinemiaMTP deficiency (no ApoB-48/100)↓↓ all lipoproteins with ApoBFat malabsorption, acanthocytosis, retinitis pigmentosa, ataxia

Cholesterol Synthesis & Bile Acid Metabolism

Cholesterol is synthesized from acetyl-CoA in the liver. The rate-limiting enzyme is HMG-CoA reductase (converts HMG-CoA to mevalonate). This enzyme is the target of statins. Cholesterol is the precursor for bile acids (7α-hydroxylase is rate-limiting), steroid hormones (all classes), and vitamin D. Bile acids (cholic, chenodeoxycholic) are conjugated with glycine or taurine, secreted into bile, and recycled via the enterohepatic circulation (terminal ileum reabsorption). Bile acid sequestrants (cholestyramine) interrupt this cycle and are used to lower LDL cholesterol and treat bile acid diarrhea.

Eicosanoid Synthesis

Eicosanoids (prostaglandins, thromboxanes, leukotrienes) are derived from arachidonic acid (a 20-carbon polyunsaturated fatty acid released from membrane phospholipids by phospholipase A2). COX-1/COX-2 produce prostaglandins and thromboxanes (NSAIDs and aspirin inhibit COX). 5-Lipoxygenase produces leukotrienes (zileuton inhibits; montelukast blocks leukotriene receptors). Corticosteroids inhibit phospholipase A2 (via lipocortin), blocking both pathways.

EicosanoidSourceKey ActionsClinical Relevance
TXA2 (thromboxane)Platelets (COX-1)Platelet aggregation, vasoconstrictionLow-dose aspirin irreversibly inhibits COX-1 in platelets (cannot regenerate COX) → anti-thrombotic
PGI2 (prostacyclin)Endothelium (COX-2)Inhibits platelet aggregation, vasodilationOpposes TXA2; endothelial cells regenerate COX → PGI2 production continues with low-dose aspirin
PGE2Many tissuesVasodilation, fever, pain sensitization, gastric mucus/HCO3 secretion, maintains PDANSAIDs → ↓PGE2 → GI ulcers, premature PDA closure. Misoprostol (PGE analog) for NSAID ulcer prophylaxis
PGFUterus, eyeUterine contraction, bronchoconstriction, ↓ intraocular pressureLatanoprost (PGF analog) for glaucoma; PGF analogs for postpartum hemorrhage
LTB4NeutrophilsNeutrophil chemotaxisKey mediator in acute inflammation
LTC4/D4/E4Mast cells, eosinophilsBronchoconstriction, vascular permeability, mucus secretion"Slow-reacting substances of anaphylaxis"; asthma treatment: montelukast, zileuton
Familial hypercholesterolemia is the most common inherited lipid disorder (~1:250 for heterozygotes). Heterozygotes have LDL ~300 mg/dL and develop CAD by age 40–50. Homozygotes have LDL >500 mg/dL and can have MI in childhood. Treatment: high-dose statins ± PCSK9 inhibitors ± ezetimibe.

19 Lysosomal Storage Diseases

Lysosomal storage diseases are inherited deficiencies of lysosomal enzymes, leading to accumulation of undigested substrates within lysosomes. Most are autosomal recessive (except Fabry and Hunter, which are X-linked).

DiseaseDeficient EnzymeAccumulated SubstrateKey Features
Tay-SachsHexosaminidase AGM2 gangliosideCherry-red macula, progressive neurodegeneration, no hepatosplenomegaly; Ashkenazi Jewish; "Tay-SaX = hexosaminidase"
Niemann-Pick (type A)SphingomyelinaseSphingomyelinCherry-red macula, hepatosplenomegaly, progressive neurodegeneration; "No Man Picks his nose with his Sphinger"
GaucherGlucocerebrosidase (β-glucosidase)GlucocerebrosideHepatosplenomegaly, pancytopenia, bone crises, "crumpled tissue paper" macrophages (Gaucher cells); most common LSD
Fabryα-Galactosidase AGlobotriaosylceramide (Gb3)X-linked; peripheral neuropathy, angiokeratomas, renal failure, corneal dystrophy ("whorl")
KrabbeGalactocerebrosidaseGalactocerebroside, psychosinePeripheral neuropathy, optic atrophy, globoid cells
Metachromatic leukodystrophyArylsulfatase ASulfatidesCentral & peripheral demyelination, ataxia, dementia
Hunter (MPS II)Iduronate-2-sulfataseHeparan sulfate, dermatan sulfateX-linked; mild Hurler-like features; NO corneal clouding (vs. Hurler)
Hurler (MPS I)α-L-iduronidaseHeparan sulfate, dermatan sulfateCorneal clouding, coarse facies, hepatosplenomegaly, intellectual disability, gargoylism
Distinguishing Features

Cherry-red macula: Tay-Sachs and Niemann-Pick (also central retinal artery occlusion). Hepatosplenomegaly: Niemann-Pick, Gaucher (NOT Tay-Sachs). X-linked: Fabry and Hunter ("Fabry and the Hunter are X-men"). Enzyme replacement therapy (ERT) is available for Gaucher (imiglucerase), Fabry (agalsidase), Pompe (alglucosidase alfa), and several MPS types.

Sphingolipid Metabolism Overview

Sphingolipids are membrane lipids derived from ceramide (sphingosine + fatty acid). Ceramide synthesis begins with condensation of palmitoyl-CoA + serine by serine palmitoyltransferase. Adding phosphocholine yields sphingomyelin; adding sugars yields cerebrosides (one sugar) or gangliosides (oligosaccharide with sialic acid). Degradation occurs stepwise in lysosomes by specific hydrolases. Deficiency of any hydrolase causes accumulation of its substrate—the molecular basis of the sphingolipidoses listed above.

Sphingolipid Degradation Pathway

SubstrateEnzymeProductDisease if Deficient
GM2 gangliosideHexosaminidase AGM3 gangliosideTay-Sachs
SphingomyelinSphingomyelinaseCeramideNiemann-Pick A/B
GlucocerebrosideGlucocerebrosidaseCeramideGaucher
Globotriaosylceramideα-Galactosidase ALactosylceramideFabry
GalactocerebrosideGalactocerebrosidaseCeramideKrabbe
SulfatideArylsulfatase AGalactocerebrosideMetachromatic leukodystrophy
CeramideCeramidaseSphingosine + FAFarber disease

I-Cell Disease (Mucolipidosis Type II)

I-cell disease results from deficiency of GlcNAc phosphotransferase, the enzyme that adds mannose-6-phosphate (M6P) tags to lysosomal enzymes in the Golgi. Without M6P, lysosomal enzymes are secreted extracellularly instead of being directed to lysosomes. Result: intracellular lysosomes lack enzymes and fill with undigested substrates (dense "inclusion bodies" → "I-cell"). Clinically resembles severe Hurler syndrome: coarse facies, skeletal abnormalities, restricted joint mobility, psychomotor retardation. Serum lysosomal enzyme levels are elevated (misdirected into blood).

20 Amino Acid Metabolism & Inborn Errors

Amino acid catabolism involves removal of the α-amino group (via transamination to α-ketoglutarate forming glutamate, then oxidative deamination by glutamate dehydrogenase releasing NH4+) and disposal of the carbon skeleton. Ammonia is detoxified by the urea cycle in the liver.

Urea Cycle

The urea cycle converts two nitrogen atoms (one from NH4+ via carbamoyl phosphate, one from aspartate) and CO2 into urea for renal excretion. The cycle spans two compartments: the first two steps (CPS I and OTC) occur in the mitochondrial matrix; the remaining three steps (argininosuccinate synthetase, argininosuccinate lyase, arginase) occur in the cytoplasm.

EnzymeLocationReactionNotes
CPS I (rate-limiting)MitochondriaNH4+ + CO2 + 2 ATP → carbamoyl phosphateActivated by N-acetylglutamate (NAG); distinct from CPS II (pyrimidine synthesis, cytoplasmic)
OTCMitochondriaCarbamoyl phosphate + ornithine → citrullineMost common urea cycle defect (X-linked); ↑orotic acid (CP shunted to pyrimidines)
Argininosuccinate synthetaseCytoplasmCitrulline + aspartate → argininosuccinateAspartate donates the 2nd nitrogen atom; deficiency = citrullinemia type I
Argininosuccinate lyaseCytoplasmArgininosuccinate → arginine + fumarateFumarate links urea cycle to TCA cycle (aspartate-argininosuccinate shunt)
ArginaseCytoplasmArginine → urea + ornithineOrnithine is recycled back to mitochondria; urea excreted by kidneys

Defects in any urea cycle enzyme cause hyperammonemia with lethargy, vomiting, cerebral edema, and respiratory alkalosis (NH3 stimulates respiratory center). Treatment: low-protein diet, nitrogen scavengers (sodium benzoate conjugates glycine, sodium phenylbutyrate conjugates glutamine), lactulose (promotes NH3 excretion by colonic bacteria), dialysis in acute crisis.

Inborn Errors of Amino Acid Metabolism

DiseaseDeficient EnzymeAccumulatedKey Features
Phenylketonuria (PKU)Phenylalanine hydroxylase (or BH4 cofactor)Phenylalanine, phenylketonesIntellectual disability, fair skin/hair, musty body odor, eczema; detected on newborn screen; Tx: low-Phe diet, BH4
Maple syrup urine diseaseBranched-chain α-ketoacid dehydrogenaseBCAAs (Ile, Leu, Val) & α-keto acidsSweet-smelling urine, intellectual disability, feeding difficulty; Tx: restrict BCAAs, thiamine trial
HomocystinuriaCystathionine β-synthase (most common) or methionine synthaseHomocysteine, methionineMarfanoid habitus, lens subluxation (downward), intellectual disability, thromboembolism, osteoporosis; Tx: B6, B12, folate, restrict Met
CystinuriaRenal PCT transporter (dibasic AAs)Cystine in urineRecurrent kidney stones (cystine = hexagonal crystals); Tx: hydration, alkalinize urine, penicillamine
AlkaptonuriaHomogentisic acid oxidaseHomogentisic acidDark urine on standing, ochronosis (blue-black pigmentation of cartilage), early arthritis
Hartnup diseaseNeutral amino acid transporter (gut/kidney)Tryptophan malabsorptionPellagra-like symptoms (tryptophan needed for niacin synthesis); neutral aminoaciduria
Homocystinuria vs. Marfan Syndrome

Both present with tall stature and long limbs. Key differentiators: Lens subluxation direction: downward in homocystinuria, upward in Marfan. Thromboembolism: present in homocystinuria, not in Marfan. Intellectual disability: present in homocystinuria, not in Marfan. Inheritance: AR in homocystinuria, AD in Marfan.

Heme Synthesis & Porphyrias

Heme synthesis begins in the mitochondria (ALA synthase: rate-limiting, requires B6, inhibited by heme) and continues in the cytoplasm before returning to mitochondria for the final step (ferrochelatase inserts Fe2+ into protoporphyrin IX). The porphyrias are enzyme deficiencies in the heme synthesis pathway.

PorphyriaDeficient EnzymeAccumulatedKey Features
Acute intermittent porphyria (AIP)Porphobilinogen deaminase (HMB synthase)PBG, ALA (urine)AD; abdominal pain, neuropsychiatric symptoms, port-wine colored urine; NO photosensitivity. Precipitated by drugs (P450 inducers), fasting, alcohol. Tx: hemin, glucose loading.
Porphyria cutanea tarda (PCT)Uroporphyrinogen decarboxylaseUroporphyrinMost common porphyria; photosensitivity (blistering skin on sun-exposed areas), hypertrichosis, tea-colored urine. Associated with hepatitis C, alcohol, iron overload. Tx: phlebotomy, hydroxychloroquine.
Erythropoietic protoporphyriaFerrochelataseProtoporphyrin IXPainful photosensitivity in childhood (immediate burning, not blistering); elevated free erythrocyte protoporphyrin.
Lead poisoningInhibits ALA dehydratase & ferrochelataseALA, protoporphyrin IXMimics porphyria; basophilic stippling, microcytic anemia, abdominal colic, lead lines on gums/bones, wrist drop, encephalopathy in children
Lead poisoning is a critical "pseudoporphyria" that inhibits two enzymes in heme synthesis: ALA dehydratase (coproporphyrinogen) and ferrochelatase. Elevated free erythrocyte protoporphyrin (FEP) and ringed sideroblasts on bone marrow biopsy are seen. In children, blood lead level ≥5 μg/dL is concerning. Treatment: succimer (oral chelation for mild cases), EDTA + dimercaprol for severe/encephalopathic cases.

21 Purine & Pyrimidine Metabolism

Purines (adenine, guanine) are synthesized de novo on a ribose-5-phosphate scaffold (from the PPP) using amino acids (Gly, Asp, Gln), CO2, and THF derivatives. IMP is the first purine nucleotide formed. Pyrimidines (cytosine, uracil, thymine) are built as a free base first (orotate), then attached to ribose-5-phosphate.

Key Enzymes & Pharmacological Targets

EnzymePathwayRelevance
PRPP synthetasePurine & pyrimidine synthesisOveractivity → gout (↑ uric acid)
HGPRT (hypoxanthine-guanine phosphoribosyltransferase)Purine salvageDeficiency → Lesch-Nyhan syndrome
Xanthine oxidasePurine degradationConverts hypoxanthine → xanthine → uric acid; target of allopurinol
Dihydrofolate reductase (DHFR)THF regeneration (purine & pyrimidine synthesis)Target of methotrexate, trimethoprim, pyrimethamine
Thymidylate synthasedTMP synthesisTarget of 5-fluorouracil (5-FU)
Ribonucleotide reductasedNTP synthesis (DNA)Target of hydroxyurea (also induces HbF)
Dihydroorotate dehydrogenasePyrimidine synthesisTarget of leflunomide (RA treatment)

Gout & Lesch-Nyhan Syndrome

Gout: hyperuricemia → monosodium urate crystal deposition in joints, causing acute inflammatory arthritis. Negatively birefringent, needle-shaped crystals under polarized light. Treatment: acute (NSAIDs, colchicine, steroids); chronic (allopurinol [xanthine oxidase inhibitor], febuxostat, probenecid [uricosuric]).

Lesch-Nyhan syndrome: X-linked deficiency of HGPRT → excess purine synthesis (cannot salvage) → severe hyperuricemia, gout, intellectual disability, self-mutilating behavior (lip and finger biting), choreoathetosis. Mnemonic: "HGPRT—He's Got Purine Recovery Trouble."

Adenosine Deaminase (ADA) Deficiency

ADA deficiency causes severe combined immunodeficiency (SCID). ADA normally converts adenosine and deoxyadenosine to inosine and deoxyinosine. When ADA is absent, deoxyadenosine accumulates and is phosphorylated to dATP, which inhibits ribonucleotide reductase. This prevents DNA synthesis, particularly devastating to lymphocytes (which rely heavily on de novo nucleotide synthesis). Result: absent T cells and B cells → life-threatening infections from infancy. Treatment: enzyme replacement (PEG-ADA), hematopoietic stem cell transplant, or gene therapy (one of the first successful gene therapy targets).

Pseudogout vs. Gout

FeatureGout (Urate)Pseudogout (CPPD)
CrystalMonosodium urateCalcium pyrophosphate dihydrate (CPPD)
ShapeNeedle-shapedRhomboid-shaped
BirefringenceStrongly negatively birefringent (yellow when parallel to polarizer)Weakly positively birefringent (blue when parallel)
Joint(s)1st MTP (podagra), ankles, kneesKnee (most common), wrists
X-rayTophi, "punched-out" erosions with overhanging edgesChondrocalcinosis (calcification of articular cartilage)
AssociationsHyperuricemia, alcohol, purine-rich diet, thiazides, tumor lysisHyperparathyroidism, hemochromatosis, hypomagnesemia, hypothyroidism

Purine vs. Pyrimidine Synthesis Comparison

FeaturePurine SynthesisPyrimidine Synthesis
Ring assemblyBuilt on ribose-5-phosphate scaffold (PRPP)Ring assembled first (as orotate), then attached to ribose
First committed step enzymeGlutamine-PRPP amidotransferaseCPS II (cytoplasmic; distinct from CPS I of urea cycle)
Atoms contributed byGly, Asp, Gln, CO2, N10-formyl-THFGln, Asp, CO2
Feedback inhibitionAMP, GMP, IMP inhibit amidotransferaseUTP inhibits CPS II
Salvage pathwayHGPRT (hypoxanthine/guanine), APRT (adenine)Thymidine kinase, uridine kinase
Degradation end productUric acid (by xanthine oxidase)CO2, NH3, β-alanine (water-soluble, readily excreted)

Chemotherapy Targeting Nucleotide Metabolism

DrugTargetMechanismClinical Use
MethotrexateDHFR (dihydrofolate reductase)Inhibits THF regeneration → ↓dTMP and purine synthesisLeukemia, RA, ectopic pregnancy; rescued with leucovorin (folinic acid)
5-Fluorouracil (5-FU)Thymidylate synthase5-FdUMP irreversibly inhibits dTMP synthesisColorectal, breast, head/neck cancers
6-Mercaptopurine (6-MP)Purine synthesis (multiple)Purine analog blocks de novo synthesisALL; metabolized by TPMT (check genotype) and xanthine oxidase (dose reduce with allopurinol)
HydroxyureaRibonucleotide reductaseInhibits conversion of NDP → dNDPCML, sickle cell disease (also induces HbF); myelosuppressive
MycophenolateIMP dehydrogenaseBlocks GMP synthesis → selective lymphocyte inhibitionTransplant rejection prophylaxis, lupus nephritis
Orotic aciduria: elevated urinary orotic acid. Two important causes: (1) OTC deficiency (urea cycle defect; orotic acid elevated because carbamoyl phosphate is shunted to pyrimidine synthesis; also has hyperammonemia). (2) Hereditary orotic aciduria (UMP synthase deficiency; megaloblastic anemia not responsive to B12/folate; no hyperammonemia; Tx: uridine supplementation).

22 Fat-Soluble Vitamins (A, D, E, K)

Fat-soluble vitamins are absorbed with dietary fat via micelles, transported in chylomicrons, and stored in liver and adipose tissue. Deficiency may result from fat malabsorption (e.g., cystic fibrosis, celiac disease, cholestasis, short bowel syndrome, pancreatic insufficiency).

VitaminActive Form / FunctionDeficiencyToxicity
A (retinol)Retinal (vision), retinoic acid (gene expression, differentiation), retinol (antioxidant). Component of rhodopsin in rod cells.Night blindness (nyctalopia), Bitot spots (conjunctival keratinization), xerophthalmia, dry skin, immune suppression, keratomalaciaPseudotumor cerebri (IIH), hepatotoxicity, teratogenesis (isotretinoin), skin peeling
D (cholecalciferol)1,25-(OH)2D3 (calcitriol): increases intestinal Ca2+ & PO43− absorption, promotes bone mineralization. Synthesized in skin (UV-B), hydroxylated in liver (25-OH) then kidney (1,25-OH).Rickets (children): bowed legs, craniotabes, rachitic rosary. Osteomalacia (adults): bone pain, proximal myopathy, ↓Ca2+, ↓PO4, ↑ALP, ↑PTHHypercalcemia: nausea, polyuria, nephrocalcinosis, metastatic calcification
E (tocopherol)Antioxidant (protects cell membranes from lipid peroxidation by scavenging free radicals)Hemolytic anemia (especially premature infants), posterior column & spinocerebellar degeneration (ataxia), peripheral neuropathyMay increase bleeding risk (potentiates warfarin)
K (phylloquinone/menaquinone)Cofactor for γ-carboxylation of glutamate residues on clotting factors II, VII, IX, X, protein C & S. Activated by vitamin K epoxide reductase (target of warfarin).Bleeding diathesis: ↑PT/INR. Hemorrhagic disease of the newborn (neonatal vitamin K deficiency).Hemolytic anemia in neonates (if given excess menadione/K3)

Fat-Soluble Vitamin Absorption

Fat-soluble vitamins (A, D, E, K) require bile salts for micelle formation and intestinal absorption. Any condition causing fat malabsorption will lead to deficiency of all four vitamins: cystic fibrosis (pancreatic insufficiency), celiac disease (villous atrophy), Crohn disease (terminal ileum), cholestatic liver disease (bile flow obstruction), short bowel syndrome, and chronic pancreatitis. Patients with these conditions require supplementation and monitoring of fat-soluble vitamin levels.

Vitamin A & Retinoid Signaling

Vitamin A exists in three active forms: retinal (component of rhodopsin in rod cells, essential for dark adaptation), retinoic acid (binds nuclear receptors RAR/RXR to regulate gene expression, cell differentiation, and immune function), and retinol (transport and storage form). Retinoic acid is critical for epithelial integrity and immune function. Its role in cell differentiation is exploited therapeutically: all-trans retinoic acid (ATRA) is used to treat acute promyelocytic leukemia (APL; PML-RARa fusion), inducing differentiation of promyelocytes. Isotretinoin (13-cis-retinoic acid) is used for severe acne but is a potent teratogen (iPLEDGE program required).

Vitamin D Metabolism in Detail

The vitamin D pathway: (1) 7-dehydrocholesterol in skin is converted to cholecalciferol (D3) by UV-B radiation. (2) Liver 25-hydroxylase produces 25-OH-D3 (calcidiol)—the best clinical measure of vitamin D status. (3) Kidney 1α-hydroxylase produces 1,25-(OH)2D3 (calcitriol)—the most active form. 1α-Hydroxylase is stimulated by PTH and low phosphate, and inhibited by FGF-23 and high calcium/phosphate. Calcitriol acts on intestine (↑Ca2+ and PO4 absorption), bone (mobilization of Ca2+/PO4), and kidney (↑Ca2+ reabsorption). Vitamin D2 (ergocalciferol) is plant-derived and undergoes the same hydroxylation steps.

All neonates receive a vitamin K injection at birth to prevent hemorrhagic disease of the newborn. Vitamin K deficiency prolongs PT (extrinsic pathway factors II, VII, IX, X are affected, but VII has the shortest half-life so PT rises first). Warfarin works by inhibiting vitamin K epoxide reductase (VKORC1).

23 Water-Soluble Vitamins (B Complex & C)

Water-soluble vitamins generally serve as enzyme cofactors. They are not stored extensively (except B12 in liver, lasting 3–5 years), so deficiencies develop more rapidly than fat-soluble vitamin deficiencies.

VitaminCofactor Form / FunctionDeficiency Syndrome
B1 (thiamine)TPP: cofactor for pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, transketolase (PPP), branched-chain α-ketoacid dehydrogenaseBeriberi: wet (high-output cardiac failure, edema) or dry (peripheral neuropathy, muscle wasting). Wernicke-Korsakoff: confusion, ataxia, ophthalmoplegia (Wernicke); confabulation, memory loss (Korsakoff). Common in alcoholism.
B2 (riboflavin)FAD, FMN: cofactors in redox reactions (ETC Complex I & II, fatty acid oxidation)Cheilosis (cracking at corners of mouth), glossitis, corneal vascularization, normocytic anemia
B3 (niacin)NAD+, NADP+: redox coenzymes. Derived from tryptophan (requires B2, B6).Pellagra: 3 D's — Diarrhea, Dermatitis (sun-exposed, Casal necklace), Dementia (+ Death if untreated). Seen in alcoholism, Hartnup disease, carcinoid syndrome, isoniazid use.
B5 (pantothenic acid)CoA, fatty acid synthase (ACP): essential for TCA cycle, fatty acid metabolismRare; dermatitis, enteritis, alopecia, adrenal insufficiency ("burning feet syndrome")
B6 (pyridoxine)PLP: cofactor for transamination, decarboxylation, heme synthesis (ALA synthase), neurotransmitter synthesis (serotonin, dopamine, GABA, histamine), cystathionine synthasePeripheral neuropathy, sideroblastic anemia (impaired heme synthesis), seizures (decreased GABA). Caused by isoniazid (INH binds PLP). Tx: supplement B6 with INH.
B7 (biotin)Cofactor for carboxylases: pyruvate carboxylase, acetyl-CoA carboxylase, propionyl-CoA carboxylaseDermatitis, alopecia, enteritis. Caused by excessive raw egg white consumption (avidin binds biotin) or prolonged antibiotics.
B9 (folate)THF: one-carbon carrier for purine synthesis, dTMP synthesis (thymidylate synthase), methionine regenerationMegaloblastic anemia (hypersegmented neutrophils, macrocytic RBCs), neural tube defects in pregnancy. Deficiency in first months of restricted diet (no hepatic stores like B12).
B12 (cobalamin)Cofactor for methionine synthase (homocysteine → methionine; requires B9) and methylmalonyl-CoA mutaseMegaloblastic anemia + neurological symptoms (subacute combined degeneration: posterior columns, lateral corticospinal tracts, peripheral neuropathy). ↑ Homocysteine AND ↑ methylmalonic acid (distinguishes from folate deficiency). Causes: pernicious anemia, vegan diet, Diphyllobothrium latum, gastrectomy, Crohn terminal ileum.
C (ascorbic acid)Cofactor for prolyl & lysyl hydroxylase (collagen synthesis), dopamine β-hydroxylase (NE synthesis), iron absorption (Fe3+ → Fe2+)Scurvy: swollen bleeding gums, perifollicular hemorrhage, petechiae, poor wound healing, corkscrew hairs, subperiosteal hemorrhage, anemia. Weakness reflects impaired collagen & carnitine synthesis.
B12 vs. Folate Deficiency

Both cause megaloblastic anemia with hypersegmented neutrophils. Both elevate homocysteine. Only B12 deficiency elevates methylmalonic acid (MMA) and causes neurological damage (subacute combined degeneration). Administering folate to a patient with undiagnosed B12 deficiency can correct the anemia but will NOT prevent neurological deterioration—making it critical to check B12 before treating with folate alone.

Thiamine (B1) Deficiency in Detail

Thiamine pyrophosphate (TPP) is the cofactor for four critical enzyme complexes: pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, branched-chain α-ketoacid dehydrogenase, and transketolase (PPP). Alcoholism is the most common cause of B1 deficiency in developed countries (poor intake, impaired absorption, increased demand). Wernicke encephalopathy is a medical emergency: classic triad of confusion, ophthalmoplegia (CN VI palsy), and ataxia (cerebellar). If untreated, it progresses to Korsakoff syndrome: irreversible anterograde amnesia with confabulation (mammillary body and dorsomedial thalamic nuclei damage). Treatment: IV thiamine BEFORE glucose administration (glucose metabolism consumes B1 and can precipitate Wernicke in a thiamine-depleted patient).

Niacin (B3) Pharmacology

At pharmacological doses, niacin lowers triglycerides and LDL while raising HDL (most effective HDL-raising agent). It inhibits lipolysis in adipose tissue (reducing hepatic VLDL production). Major side effect: flushing (prostaglandin-mediated cutaneous vasodilation); reduced by aspirin pretreatment or extended-release formulation. Other adverse effects: hyperglycemia, hyperuricemia, hepatotoxicity.

Folate & Neural Tube Defects

Folate supplementation (400 μg/day) beginning at least one month before conception and continuing through the first trimester dramatically reduces the incidence of neural tube defects (anencephaly, spina bifida). Women with a prior NTD-affected pregnancy should take 4 mg/day. Folate fortification of grain products (mandatory in the US since 1998) has reduced NTD incidence by ~25–30%. Methotrexate and other antifolates are teratogenic and absolutely contraindicated in pregnancy.

Vitamin Toxicity Quick-Reference

VitaminToxicity FindingsMechanism
A (hypervitaminosis A)Pseudotumor cerebri (headache, papilledema), hepatotoxicity, skin desquamation, teratogenesisRetinoic acid excess disrupts cell differentiation; fat-soluble → accumulates
DHypercalcemia: nausea, vomiting, polyuria, constipation, renal stones, nephrocalcinosis, metastatic calcificationExcess calcitriol ↑Ca2+ absorption and bone resorption
EIncreased bleeding risk, potentiation of warfarinInhibits vitamin K-dependent carboxylation at high doses
B6 (megadose)Peripheral sensory neuropathy (ataxia, loss of proprioception)Direct neurotoxicity at doses >200 mg/day chronically
B3 (niacin)Flushing, hyperglycemia, hyperuricemia, hepatotoxicityProstaglandin-mediated vasodilation; metabolic effects at pharmacological doses
C (megadose)Nausea, diarrhea, increased oxalate kidney stones, false-negative guaiac testExcess oxalate production; reducing agent interferes with tests

24 Minerals, Trace Elements & Nutrition

Minerals and trace elements serve as enzyme cofactors, structural components, and electrolytes essential for physiological function.

Key Minerals & Trace Elements

ElementFunctionDeficiencyExcess / Notes
Iron (Fe)Heme (hemoglobin, myoglobin, cytochromes), FeS clusters in ETCMicrocytic hypochromic anemia, pica, koilonychia, ↓ferritin, ↑TIBCHemochromatosis (HFE mutation): bronze skin, cirrhosis, DM, cardiomyopathy, arthropathy
Copper (Cu)Lysyl oxidase, ceruloplasmin, cytochrome c oxidase, SOD, dopamine β-hydroxylase, tyrosinaseMenkes disease (X-linked Cu transport defect): kinky hair, connective tissue laxity, neurodegenerationWilson disease (AR, ATP7B mutation): Kayser-Fleischer rings, hepatolenticular degeneration, psychiatric symptoms, low ceruloplasmin
Zinc (Zn)Metalloenzymes (carbonic anhydrase, alcohol dehydrogenase, collagenase), wound healing, immunity, taste/smellAcrodermatitis enteropathica (AR), delayed wound healing, hypogeusia, anosmia, impaired immunity, hypogonadismCan cause copper deficiency (zinc induces metallothionein which sequesters Cu)
Selenium (Se)Glutathione peroxidase, thioredoxin reductase, deiodinasesKeshan disease (cardiomyopathy), Kashin-Beck disease (osteoarthropathy)Garlic breath, hair/nail loss, GI upset
Chromium (Cr)Glucose tolerance factor (potentiates insulin)Impaired glucose tolerance, peripheral neuropathyRare toxicity
Fluoride (F)Incorporated into hydroxyapatite (fluoroapatite) strengthening enamelDental cariesFluorosis (mottled enamel, skeletal fluorosis)

Nutrition Disorders

Kwashiorkor: protein malnutrition with adequate caloric intake. Features: edema (low albumin → low oncotic pressure), fatty liver, skin lesions, flag sign (alternating pigmented/depigmented hair bands), preserved fat stores. Marasmus: total calorie deficiency. Features: muscle wasting, loss of subcutaneous fat, emaciation, no edema. Refeeding syndrome: occurs when malnourished patients are fed too quickly. Insulin surge drives PO43−, K+, and Mg2+ into cells → dangerous hypophosphatemia → cardiac arrhythmias, respiratory failure, rhabdomyolysis.

Iron Metabolism

Dietary iron is absorbed in the duodenum as heme iron (from meat, directly absorbed) or non-heme ferric iron (Fe3+, reduced to Fe2+ by duodenal cytochrome B, then transported by DMT-1). Inside enterocytes, iron is either stored as ferritin or exported by ferroportin (the only known iron exporter). In blood, iron is bound to transferrin and delivered to cells via transferrin receptor. Hepcidin, produced by the liver, is the master regulator: it degrades ferroportin, reducing iron absorption and release from macrophages. Hepcidin is upregulated by iron excess and inflammation (explaining anemia of chronic disease) and downregulated by iron deficiency, erythropoietic activity, and hypoxia.

ConditionFerritinSerum IronTIBCTransferrin SatHepcidin
Iron deficiency anemia
Anemia of chronic disease↑ (or normal)
Hemochromatosis↑↑↑↑
Sideroblastic anemiaVariable
Pregnancy

Wilson Disease vs. Hemochromatosis

FeatureWilson Disease (Copper)Hemochromatosis (Iron)
InheritanceAR (ATP7B gene, chr 13)AR (HFE gene, chr 6; C282Y mutation)
PathophysiologyImpaired biliary copper excretion → copper accumulationExcessive iron absorption (low hepcidin) → iron deposition
LiverHepatitis, cirrhosis, acute liver failureCirrhosis, hepatocellular carcinoma
NeuropsychiatricTremor, dysarthria, personality change, depressionUncommon
Pathognomonic signKayser-Fleischer rings (copper in Descemet membrane)Bronze skin pigmentation
Lab findings↓ Ceruloplasmin, ↑ urine copper, ↑ hepatic copper↑↑ Ferritin, ↑ transferrin saturation, HFE genotyping
Other organsHemolytic anemia (Coombs-negative), renal tubular defectsDiabetes ("bronze diabetes"), cardiomyopathy, arthropathy, hypogonadism
TreatmentPenicillamine or trientine (copper chelation), zinc (blocks absorption)Phlebotomy (first-line), deferoxamine (iron chelation)
Refeeding syndrome is a medical emergency. The key derangement is severe hypophosphatemia. Prevention: advance nutrition slowly in malnourished patients, supplement phosphate/potassium/magnesium, and monitor electrolytes closely during the first 3–5 days of refeeding.

25 Molecular Biology & DNA Repair

The central dogma of molecular biology describes the flow of genetic information: DNA → RNA (transcription) → Protein (translation). Understanding these processes is essential for interpreting molecular diagnostics and understanding antibiotic and chemotherapeutic mechanisms.

DNA Replication

Replication is semiconservative, bidirectional, and proceeds 5′ → 3′. Helicase unwinds the double helix. Topoisomerase relieves supercoiling (fluoroquinolones inhibit bacterial topoisomerase II/DNA gyrase). Primase synthesizes RNA primers. DNA polymerase III (prokaryotes) / Pol δ and Pol ε (eukaryotes) elongate the new strand. Leading strand is synthesized continuously; lagging strand is synthesized as Okazaki fragments, joined by DNA ligase. Telomerase (a reverse transcriptase) maintains telomere length in germ cells, stem cells, and most cancer cells.

DNA Repair Mechanisms

Repair MechanismType of DamageKey FeaturesDisease if Defective
Nucleotide excision repair (NER)Bulky DNA adducts, thymine dimers (UV damage)Excises oligonucleotide containing lesionXeroderma pigmentosum (extreme UV sensitivity, skin cancers)
Base excision repair (BER)Small base modifications (deamination, oxidation, methylation)Glycosylase removes damaged base → AP endonuclease → gap filledRare; MUTYH-associated polyposis
Mismatch repair (MMR)Mismatched bases from replication errorsMSH2/MLH1 recognize mismatches on new strandLynch syndrome (hereditary nonpolyposis colorectal cancer, HNPCC)
Homologous recombinationDouble-strand breaksUses sister chromatid as template; error-freeBRCA1/BRCA2 mutations → breast/ovarian cancer
Non-homologous end joining (NHEJ)Double-strand breaksJoins broken ends directly; error-proneMay introduce mutations; used throughout cell cycle

Key Antibiotics & Their Molecular Targets

TargetDrug(s)Mechanism
DNA gyrase / Topoisomerase IVFluoroquinolones (ciprofloxacin, levofloxacin)Prevent supercoil relaxation → block replication
RNA polymeraseRifampinInhibits bacterial DNA-dependent RNA polymerase
30S ribosomal subunitAminoglycosides, tetracyclinesAminoglycosides: misread mRNA; Tetracyclines: block tRNA binding
50S ribosomal subunitMacrolides, chloramphenicol, clindamycin, linezolidBlock translocation or peptidyl transfer
Folate synthesisSulfonamides (DHPS), Trimethoprim (DHFR)Block sequential steps in folate pathway

Transcription

RNA polymerase synthesizes RNA 5′ → 3′ from a DNA template (read 3′ → 5′). Eukaryotes have three RNA polymerases: Pol I (rRNA, except 5S), Pol II (mRNA, snRNA, miRNA), Pol III (tRNA, 5S rRNA). α-Amanitin (Amanita phalloides mushroom toxin) inhibits RNA Pol II → hepatotoxicity. Eukaryotic mRNA is processed: 5′ cap (7-methylguanosine, added by guanylyltransferase), 3′ poly-A tail (added by poly-A polymerase), and splicing (introns removed by the spliceosome). The 5′ cap is critical for ribosome recognition and mRNA stability.

Translation

Translation occurs on ribosomes (80S in eukaryotes = 40S + 60S; 70S in prokaryotes = 30S + 50S). The process involves three stages: Initiation (small subunit binds mRNA, start codon AUG recognized, Met-tRNA loaded), Elongation (aminoacyl-tRNA binds A site, peptidyl transferase forms peptide bond, ribosome translocates), and Termination (stop codons UAA, UAG, UGA; release factors). Diphtheria toxin inactivates EF-2 (elongation factor 2) via ADP-ribosylation. Pseudomonas exotoxin A has the same mechanism.

Genetic Code Features

FeatureDescriptionClinical Significance
Degeneracy (redundancy)Multiple codons encode the same amino acid (64 codons for 20 AAs + stop signals)3rd position "wobble" allows single tRNA to recognize multiple codons; some point mutations are silent
UnambiguousEach codon specifies only one amino acidNo ambiguity in translation
UniversalNearly all organisms use the same codeExceptions: mitochondria, some protists; allows recombinant DNA technology
Commaless & non-overlappingRead in continuous triplets without gaps or overlapsFrameshift mutations (insertions/deletions not multiple of 3) are devastating
Start codonAUG (methionine in eukaryotes, fMet in prokaryotes)First AUG in mRNA sets reading frame
Stop codonsUAA, UAG, UGAUGA also encodes selenocysteine with SECIS element

Types of Mutations

Mutation TypeDescriptionExample
SilentNucleotide change, same amino acid (3rd position wobble)No phenotypic effect
MissenseNucleotide change, different amino acidSickle cell (GAG → GTG; Glu → Val)
NonsenseNucleotide change creates premature stop codonTruncated protein; often β-thalassemia
FrameshiftInsertion or deletion (not multiple of 3)Tay-Sachs (4-bp insertion in hexosaminidase A)
Splice siteMutation at intron-exon junctionSome β-thalassemia mutations
Trinucleotide repeat expansionRepeat sequence expands beyond thresholdHuntington (CAG), Fragile X (CGG), Myotonic dystrophy (CTG), Friedreich ataxia (GAA)

Cell Signaling Pathways

PathwayReceptor TypeKey MediatorsClinical Example
cAMP (Gs)GPCRGs → adenylyl cyclase → cAMP → PKACholera toxin: constitutive Gs activation → ↑cAMP → secretory diarrhea
cAMP (Gi)GPCRGi inhibits adenylyl cyclase → ↓cAMPPertussis toxin: inactivates Gi → ↑cAMP → whooping cough symptoms
IP3/DAG (Gq)GPCRGq → PLC → IP3 (↑Ca2+) + DAG (→PKC)α1-adrenergic receptors, H1 histamine, vasopressin V1
Receptor tyrosine kinaseRTKRas → Raf → MEK → ERK (MAP kinase cascade)Insulin receptor, EGF receptor; oncogenes (RAS mutations in cancers)
JAK-STATCytokine receptorJAK phosphorylates STATs → dimerize → nuclear translocationErythropoietin, growth hormone, interferons; JAK2 mutation in polycythemia vera
Steroid receptorIntracellular/nuclearLigand-receptor complex acts as transcription factorCortisol, estrogen, testosterone, thyroid hormone, vitamin D
Lynch syndrome (HNPCC) is caused by defective mismatch repair (MLH1, MSH2, MSH6, PMS2 mutations). It follows the Amsterdam criteria (3-2-1 rule): 3 relatives with Lynch-associated cancer, spanning 2 generations, with 1 case diagnosed before age 50. Microsatellite instability (MSI) testing and immunohistochemistry for MMR proteins are used for diagnosis.

26 Clinical Correlates & Metabolic Integration

Metabolic pathways do not operate in isolation; they are interconnected, hormonally regulated, and tissue-specific. Understanding the fed vs. fasted metabolic states and the integration of major pathways is essential for clinical reasoning.

Fed vs. Fasted State

ParameterFed State (Insulin High)Fasting State (Glucagon High)
LiverGlycogenesis, lipogenesis, protein synthesisGlycogenolysis, gluconeogenesis, ketogenesis, β-oxidation
MuscleGlucose uptake (GLUT4), glycogenesis, protein synthesisProteolysis (Ala → liver for gluconeogenesis), fatty acid oxidation
AdiposeLipogenesis, glucose uptake (GLUT4), LPL activity ↑Lipolysis (hormone-sensitive lipase activated by glucagon/epi)
BrainGlucose as primary fuel (GLUT1, insulin-independent)Glucose initially; ketone bodies during prolonged fasting (>2–3 days)
RBCsGlycolysis only (no mitochondria)Glycolysis only; glucose is essential fuel

Rate-Limiting Enzymes of Major Pathways

PathwayRate-Limiting EnzymeKey Regulators
GlycolysisPFK-1AMP, F2,6BP (↑); ATP, citrate (↓)
GluconeogenesisFructose-1,6-bisphosphataseCitrate, ATP (↑); AMP, F2,6BP (↓)
TCA cycleIsocitrate dehydrogenaseADP (↑); ATP, NADH (↓)
GlycogenesisGlycogen synthaseInsulin, G6P (↑); glucagon, epi (↓)
GlycogenolysisGlycogen phosphorylaseGlucagon, epi, AMP (↑); insulin, G6P, ATP (↓)
FA synthesisAcetyl-CoA carboxylase (ACC)Insulin, citrate (↑); glucagon, palmitoyl-CoA (↓)
β-OxidationCPT-IGlucagon (↑); malonyl-CoA (↓)
KetogenesisHMG-CoA synthase↑ in fasting/starvation/DKA
Cholesterol synthesisHMG-CoA reductaseInsulin (↑); glucagon, cholesterol (↓); target of statins
Urea cycleCPS IN-acetylglutamate (↑)
PPPG6PDNADP+ (↑); NADPH (↓)
Pyrimidine synthesisCPS IIATP, PRPP (↑); UTP (↓)
Purine synthesisGlutamine-PRPP amidotransferasePRPP (↑); AMP, GMP, IMP (↓)
Heme synthesisALA synthaseHeme (↓, feedback); B6 (cofactor)

Metabolic Fuel Sources by Duration of Fasting

0–4 hours: dietary glucose, hepatic glycogenolysis. 4–16 hours: hepatic glycogenolysis, gluconeogenesis begins. 16–48 hours: hepatic glycogen depleted; gluconeogenesis (from amino acids, glycerol, lactate) is primary glucose source; fatty acid oxidation increases. >2–3 days: ketogenesis accelerates; brain switches to ketone bodies (sparing glucose and muscle protein). Weeks of starvation: ketones supply ~75% of brain fuel; muscle proteolysis slows to preserve lean mass.

Tissue-Specific Metabolism

TissuePreferred Fuel(s)Key Metabolic Features
BrainGlucose (normally); ketones (fasting)Cannot use fatty acids (don't cross BBB); GLUT1/3 (insulin-independent); high O2 demand
RBCsGlucose (exclusively)No mitochondria → only glycolysis; no TCA, no ETC, no β-oxidation; produce 2,3-BPG via Rapoport-Luebering shunt
LiverAmino acids, fatty acids, glucoseMetabolic hub: gluconeogenesis, ketogenesis, ureagenesis, bile acid synthesis, VLDL production. Glucokinase (not hexokinase), has glucose-6-phosphatase
Skeletal muscleFatty acids (rest); glucose (exercise)GLUT4 (insulin-dependent); glycogen for local use only (no G6Pase); produces lactate (anaerobic) and alanine (Cori/alanine cycles)
Cardiac muscleFatty acids (>70%), ketones, lactate, glucoseHighly aerobic (abundant mitochondria); can use lactate as fuel (LDH-1 predominant); most versatile fuel use
Adipose tissueFatty acidsGLUT4; stores TGs; hormone-sensitive lipase releases FFAs in fasting; lipoprotein lipase on capillaries clears circulating TGs
KidneyFatty acids, glutamineGluconeogenesis (especially in prolonged fasting); NH4+ excretion from glutamine for acid-base balance
Metabolic Effects of Alcohol

Ethanol is metabolized by alcohol dehydrogenase (ADH) and then aldehyde dehydrogenase (ALDH), generating excess NADH. The high NADH/NAD+ ratio shifts equilibria: (1) Pyruvate → lactate (lactic acidosis). (2) OAA → malate (inhibits gluconeogenesis → fasting hypoglycemia). (3) DHAP → glycerol-3-phosphate (promotes TG synthesis → fatty liver). (4) Inhibits β-oxidation. Clinical: alcoholic fatty liver, hypoglycemia, lactic acidosis, hyperuricemia (lactate competes with urate for renal excretion).

Insulin & Glucagon Signaling Integration

HormoneSignalMetabolic Effects
InsulinTyrosine kinase receptor → IRS-1 → PI3K → Akt (PKB) → GLUT4 translocation; also RAS-MAPK for growth↑ Glycolysis, glycogenesis, lipogenesis, protein synthesis, K+ uptake. ↓ Gluconeogenesis, glycogenolysis, lipolysis, ketogenesis.
GlucagonGPCR → Gs → adenylyl cyclase → cAMP → PKA↑ Glycogenolysis, gluconeogenesis, lipolysis, β-oxidation, ketogenesis. ↓ Glycolysis, glycogenesis, lipogenesis.
EpinephrineSame as glucagon in liver; β2 (muscle/liver) and α1 (IP3/Ca2+)↑ Glycogenolysis (muscle & liver), lipolysis, gluconeogenesis. Muscle: ↑ glycolysis for immediate energy.
CortisolNuclear receptor → gene transcription↑ Gluconeogenesis (PEPCK induction), proteolysis, lipolysis. Permissive for glucagon/epi effects. Chronic: hyperglycemia, central obesity, immunosuppression.

GLUT Transporters

TransporterTissue(s)Key Features
GLUT1RBCs, brain, cornea, placentaBasal glucose uptake; insulin-independent; constitutively active
GLUT2Liver, β-islet cells, kidney, small intestineBidirectional, high capacity, low affinity; "glucose sensor" in β-cells
GLUT3NeuronsLow Km (high affinity); ensures brain gets glucose even at low levels
GLUT4Adipose, skeletal muscleInsulin-dependent: insulin triggers GLUT4 vesicle fusion with membrane. Defective in type 2 DM (insulin resistance).
GLUT5Small intestine (enterocytes), spermatozoaFructose transporter (not glucose)
SGLT1Small intestineNa+/glucose cotransporter (active transport); also galactose
SGLT2Proximal tubule (kidney)Reabsorbs ~90% filtered glucose; target of SGLT2 inhibitors (empagliflozin, dapagliflozin)
SGLT2 inhibitors represent a landmark advance in type 2 diabetes management. By blocking renal glucose reabsorption, they induce glycosuria and lower blood glucose independently of insulin. They also have proven cardiovascular and renal protective effects (reduced heart failure hospitalizations, slowed CKD progression) and are now used even in non-diabetic heart failure and CKD.

Diabetes Mellitus: Biochemical Basis

FeatureType 1 DMType 2 DM
PathogenesisAutoimmune destruction of β-cells (anti-GAD, anti-islet cell, anti-insulin antibodies)Insulin resistance → relative insulin deficiency; β-cell dysfunction over time
OnsetUsually childhood/adolescence (can occur at any age)Usually adults (increasingly in obese adolescents)
Insulin levelAbsent / very lowNormal or elevated early; decreased late
C-peptideLow / absent (no endogenous insulin)Normal or elevated
DKA riskHigh (absolute insulin deficiency)Rare (some insulin present); hyperosmolar hyperglycemic state (HHS) more typical
Metabolic stateCatabolic: ↑lipolysis, ↑β-oxidation, ↑ketogenesis, ↑proteolysis, ↑gluconeogenesisAnabolic: ↑TG storage, weight gain; metabolic syndrome
TreatmentInsulin (mandatory)Lifestyle + metformin (first-line); may need insulin eventually

Non-Enzymatic Glycation

In hyperglycemia, glucose non-enzymatically attaches to proteins (Maillard reaction), forming advanced glycation end products (AGEs). AGEs cross-link collagen in vessel walls, trap LDL (accelerating atherosclerosis), activate RAGE receptors (inducing inflammation and oxidative stress), and thicken basement membranes. This underlies diabetic microvascular complications: retinopathy, nephropathy, and neuropathy. HbA1c is a glycated hemoglobin that reflects average blood glucose over 2–3 months (RBC lifespan ~120 days). Target HbA1c <7% in most diabetic patients.

Four Pathways of Diabetic Damage

Chronic hyperglycemia damages tissues through four major biochemical mechanisms:

PathwayMechanismConsequence
Polyol (sorbitol) pathwayAldose reductase converts glucose → sorbitol (uses NADPH); sorbitol dehydrogenase converts sorbitol → fructoseOsmotic cell damage (cataracts, neuropathy); NADPH depletion → oxidative stress
Advanced glycation end productsNon-enzymatic glycation of proteins and lipidsVascular stiffening, inflammation, atherosclerosis, basement membrane thickening
Protein kinase C (PKC) activationHyperglycemia → ↑DAG → PKC activationAltered vascular permeability, angiogenesis, endothelial dysfunction
Hexosamine pathwayExcess fructose-6-phosphate → glucosamine-6-phosphate → UDP-GlcNAc → O-GlcNAcylation of proteinsAltered gene expression, TGF-β upregulation, vascular smooth muscle proliferation

27 High-Yield Review & Reference Tables

This section consolidates the most frequently tested biochemistry concepts for rapid board review.

Inborn Errors Quick-Reference

DiseaseEnzyme Defect"Buzzword" Finding
PKUPhenylalanine hydroxylaseMusty body odor, mousey urine
Maple syrup urine diseaseBranched-chain α-ketoacid DHSweet/maple urine odor
AlkaptonuriaHomogentisic acid oxidaseDark urine, ochronosis
HomocystinuriaCystathionine β-synthaseDownward lens subluxation, thrombosis
CystinuriaDibasic AA transporterHexagonal urinary crystals
Von Gierke (GSD I)Glucose-6-phosphataseSevere fasting hypoglycemia, hepatomegaly
Pompe (GSD II)Acid maltaseCardiomegaly, hypotonia
McArdle (GSD V)Muscle glycogen phosphorylaseNo lactate rise on ischemic forearm test
Tay-SachsHexosaminidase ACherry-red macula, no HSM
GaucherGlucocerebrosidase"Crumpled tissue paper" macrophages
Niemann-Pick ASphingomyelinaseCherry-red macula + HSM
Fabryα-Galactosidase AAngiokeratomas, burning extremity pain
Hurler (MPS I)α-L-iduronidaseCorneal clouding, gargoylism
Hunter (MPS II)Iduronate-2-sulfataseNO corneal clouding, X-linked
Lesch-NyhanHGPRTSelf-mutilation, hyperuricemia
G6PD deficiencyGlucose-6-phosphate DHHeinz bodies, bite cells
Hereditary fructose intoleranceAldolase BHypoglycemia after fructose ingestion
Classic galactosemiaGal-1-P uridylyltransferaseCataracts, E. coli sepsis in neonate

Vitamin Deficiency Quick-Reference

VitaminDeficiency Buzzword
ANight blindness, Bitot spots, xerophthalmia
B1 (thiamine)Beriberi, Wernicke-Korsakoff
B2 (riboflavin)Cheilosis, corneal vascularization
B3 (niacin)Pellagra (3 D's: Diarrhea, Dermatitis, Dementia)
B5 (pantothenate)Burning feet, dermatitis (rare)
B6 (pyridoxine)Sideroblastic anemia, seizures (INH use)
B7 (biotin)Dermatitis, alopecia (raw eggs/avidin)
B9 (folate)Megaloblastic anemia, neural tube defects
B12 (cobalamin)Megaloblastic anemia + subacute combined degeneration, ↑MMA
C (ascorbic acid)Scurvy: bleeding gums, petechiae, corkscrew hairs
DRickets (children), osteomalacia (adults)
EHemolytic anemia, spinocerebellar degeneration
KBleeding diathesis (↑PT), hemorrhagic disease of newborn

Key Cofactor Associations

CofactorVitamin SourceKey Enzymes
TPPB1 (thiamine)PDH, α-KG DH, transketolase, branched-chain α-ketoacid DH
FAD / FMNB2 (riboflavin)Succinate DH (Complex II), NADH DH (Complex I), acyl-CoA DH
NAD+ / NADP+B3 (niacin)Glycolysis, TCA cycle, ETC, PPP, gluconeogenesis
CoAB5 (pantothenate)PDH, α-KG DH, fatty acid synthesis/oxidation
PLPB6 (pyridoxine)Transaminases, ALA synthase, glycogen phosphorylase, decarboxylases
BiotinB7Pyruvate carboxylase, ACC, propionyl-CoA carboxylase
THFB9 (folate)Thymidylate synthase, purine synthesis, methionine synthase
Deoxyadenosylcobalamin / MethylcobalaminB12Methylmalonyl-CoA mutase, methionine synthase

Metabolic Pathway Locations

PathwayCellular Location
GlycolysisCytoplasm
GluconeogenesisCytoplasm (mostly) + mitochondria (pyruvate carboxylase) + ER (G6Pase)
TCA cycleMitochondrial matrix
Oxidative phosphorylationInner mitochondrial membrane
Fatty acid synthesisCytoplasm
β-OxidationMitochondrial matrix
KetogenesisMitochondrial matrix (liver only)
Pentose phosphate pathwayCytoplasm
Urea cycleMitochondria (CPS I, OTC) + cytoplasm (remaining steps)
Heme synthesisMitochondria (first & last steps) + cytoplasm (middle steps)
Cholesterol synthesisCytoplasm (SER)
Steroid synthesisMitochondria (side-chain cleavage) + SER (subsequent steps)
Protein synthesisRER (secreted/membrane proteins) or free ribosomes (cytoplasmic/nuclear proteins)
Glycogen synthesis/degradationCytoplasm
Peroxisomal β-oxidationPeroxisomes (VLCFA, branched-chain FA)

X-Linked Metabolic Disorders

DisorderDefectKey Feature
G6PD deficiencyGlucose-6-phosphate dehydrogenaseHemolytic anemia with oxidant stress
Fabry diseaseα-Galactosidase AAngiokeratomas, renal failure, neuropathy
Hunter syndrome (MPS II)Iduronate-2-sulfataseHurler-like but no corneal clouding
Lesch-Nyhan syndromeHGPRTHyperuricemia, self-mutilation
OTC deficiencyOrnithine transcarbamylaseHyperammonemia, elevated orotic acid
Menkes diseaseATP7A (copper transporter)Kinky hair, connective tissue laxity
AdrenoleukodystrophyABCD1 (peroxisomal VLCFA transporter)Adrenal insufficiency, CNS demyelination
Pyruvate dehydrogenase deficiencyPDH E1 subunitLactic acidosis, neurological deficits

Inheritance Patterns in Metabolic Disease

The vast majority of inborn errors of metabolism follow autosomal recessive inheritance: both parents are carriers, and each offspring has a 25% chance of being affected. Notable X-linked exceptions are listed above. Autosomal dominant metabolic disorders are rare but include familial hypercholesterolemia (LDL receptor), acute intermittent porphyria (PBG deaminase), and some forms of hereditary spherocytosis.

Laboratory Values & Metabolic Panels

Lab TestNormal RangeElevated InDecreased In
Glucose (fasting)70–100 mg/dLDiabetes, Cushing, acromegaly, pheochromocytomaInsulinoma, adrenal insufficiency, liver failure, GSD I
HbA1c<5.7%Uncontrolled diabetes (reflects 2–3 month glucose average)Hemolytic anemia, blood loss (falsely low)
Ammonia10–35 μmol/LUrea cycle defects, liver failure, Reye syndrome, valproic acidNot clinically significant
Uric acid3.5–7.2 mg/dL (M)Gout, Lesch-Nyhan, tumor lysis syndrome, von Gierke (GSD I)SIADH, allopurinol/febuxostat therapy
Lactate0.5–2.0 mEq/LTissue hypoperfusion (shock), mitochondrial disease, cyanide, CO poisoning, PDH deficiency, GSD INot clinically significant
Methylmalonic acid<0.4 μmol/LB12 deficiency, methylmalonyl-CoA mutase deficiencyNot clinically significant
Homocysteine5–15 μmol/LB12 deficiency, folate deficiency, homocystinuria, B6 deficiencyNot clinically significant
Quick Associations for Board Questions

Musty/mousey odor → PKU. Sweet/maple syrup odor → MSUD. Dark urine → alkaptonuria. Cherry-red macula → Tay-Sachs, Niemann-Pick (or CRAO). Hexagonal crystals → cystinuria. Crumpled tissue paper macrophages → Gaucher. Heinz bodies & bite cells → G6PD deficiency. Gargoylism + corneal clouding → Hurler. Self-mutilation → Lesch-Nyhan. Port-wine urine → acute intermittent porphyria. Fruity breath → DKA. Corkscrew hairs → scurvy. Casal necklace → pellagra (B3 deficiency).

Tumor Metabolism

ConceptDescriptionClinical Application
Warburg effectAerobic glycolysis: cancer cells prefer glycolysis even with adequate O2Basis for FDG-PET imaging (increased glucose uptake)
OncometabolitesIDH1/2 mutations produce 2-hydroxyglutarate (2-HG), an abnormal metabolite2-HG inhibits α-KG-dependent enzymes → hypermethylation → AML, glioma
Tumor lysis syndromeRapid cell death releases purines → xanthine oxidase → massive uric acid productionHyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia. Prevent with allopurinol or rasburicase.
Glutamine addictionMany cancers are dependent on glutamine for anaplerosis and biosynthesisGlutaminase inhibitors under investigation as anticancer agents
Exam Focus: The highest-yield biochemistry topics for USMLE Step 1 are: (1) rate-limiting enzymes and their regulation, (2) glycogen storage diseases, (3) lysosomal storage diseases, (4) amino acid metabolism inborn errors, (5) vitamin deficiencies and their cofactor roles, (6) hemoglobin oxygen-dissociation curve shifts, (7) enzyme kinetics graphs (Michaelis-Menten, Lineweaver-Burk), (8) ETC inhibitors and uncouplers, (9) fed vs. fasted metabolism, and (10) DNA repair defects and their associated cancers. For all inborn errors, know the deficient enzyme, accumulated substrate, and one or two "buzzword" clinical features.